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Abstract 
Alzheimer’s disease is the most common form of dementia, which is 
globally epidemic and well-known by the general public. Episodic memory, a 
conscious recollection of a particular event in spatial and temporal context, is the 
most prominent deficit in the early stage of clinical amnestic AD, and reflected by 
the shrinkage of structures in medial temporal lobe (MTL), including the 
hippocampus. According to Braak staging, tangles begin in the transentorhinal 
cortex of the MTL, which then spreads to hippocampal subfields, and later to 
neocortical areas. Cases that are less recognized by the general public are 
patients with the atypical variants of AD. Interestingly, many of the atypical cases 
of AD appear to share the same histopathological features with clinical amnestic 
AD. According to the diagnostic criteria for these atypical variants of AD, episodic 
memory should be relatively preserved. However, inconsistent reports on the 
episodic memory performance and the hippocampal involvement in these 
atypical cases pose challenges for accurately diagnosing these patients. The two 
kinds of atypical variants of AD that I focused here are logopenic variant of 
Primary Progressive Aphasia (lvPPA) and posterior cortical atrophy (PCA). 
The overarching theme of my thesis is to examine 1) whether the atypical cases 
of AD have episodic memory difficulty, and if so, 2) what brain areas are 
responsible for this difficulty. Chapter 2 and 3 of the current thesis show that 1) 
episodic memory difficulty is observed in lvPPA and PCA cases and 2) this 
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impairment is modulated by deficit in other cognitive domains and associated 
with disease in non-MTL brain regions. This would be consistent with the 
‘hippocampal-sparing’ hypothesis that not all AD histopathology begins in the 
MTL, and these hippocampal-sparing conditions suggest that additional 
mechanisms must be considered in the genesis of spreading pathology in AD.   
 
Keywords: atypical variant of Alzheimer's disease, episodic memory 
(verbal/visual), Alzheimer's disease, logopenic variant of Primary Progressive 
Aphasia, lexical retrieval, posterior cortical atrophy, hippocampus/medial 
temporal lobe 
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CHAPTER I. INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of dementia, which 
is defined as a cognitive deficit in at least two domains that is also interfering with 
independence in everyday activities in elderly individuals(McKhann et al. 2011).  
By 2040, it is estimated to affect 81 million people worldwide (Gold and Budson 
2008; 2017).  Episodic memory, which allows individuals to recall personal 
experiences, is often the most prominent deficit in clinical AD, which later then 
progresses to affect multiple cognitive domains (McKhann et al. 2011).  
 
Section I.A. Memory in AD 
The most salient feature and earliest symptom of AD often is the inability 
to form new memories and retain them (Gold and Budson 2008; Arshavsky 
2010). During the early course of the disease, such impairment may result in 
forgetfulness of crucial events, including misplacing items, missing doctor 
appointments, paying bills late, and forgetting to take medications (Gold and 
Budson 2008). Memory loss is observed in both verbal and visual modalities 
(Collie and Maruff 2000).  
Verbal episodic memory may be assessed with story recall, word list 
learning or verbal paired associate tasks (Collie and Maruff 2000). Most often in 
the clinical setting, it is usually assessed with delayed free recall of a list of 
words.  Here, participants are given a list of words to remember, and they are 
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asked to recall the words after a filled delay period.  In a recognition memory test, 
participants study a list of words, and after a filled period these are later 
presented in a randomly ordered list where some were previously studied (‘old’ 
items) and some were novel (‘new’ items). Participants are then asked to identify 
whether each item on the list is ‘old’ or ‘new’. (Gold and Budson 2008) Delayed 
free recall test is a more difficult process than recognition memory test since it 
requires a lexical retrieval process (Indefrey 2011). AD patients performed poorly 
on both tasks compared to age-matched individuals (Helkala et al. 1988; Gold 
and Budson 2008; Bonner-Jackson et al. 2015). 
Visual episodic memory may be assessed in the same way. Examples 
(Collie and Maruff 2000) include Warrington’s recognition memory for faces 
(Warrington 1984), visual retention test (Benton 1945), and Rey Figure Recall 
Test (Osterrieth 1944). In clinic, it is often assessed with Rey Figure Recall Test, 
where participants are asked to copy a figure composed of geometric shapes, 
and the individual is asked to draw it from memory after a filled delayed period. 
AD patients have difficulty drawing this figure from memory after a delayed 
period (Kasai et al. 2006; Bonner-Jackson et al. 2015).   
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Section I.B. Medial temporal lobe and memory 
From lesion studies, including patient H.M., and work in neuroimaging, we 
have learned that one canonical structure responsible for memory is the medial 
temporal lobe (MTL) (Cohen and Eichenbaum 1995; Clark and Squire 2010; 
Wixted and Squire 2011a; 2011b; Eichenbaum 2013). MTL encompasses 
several histologically distinct regions (Andersen 2007; Duvernoy et al. 2013); it 
consists of hippocampus [(consisting of the cornu ammonis subfields, CA1, CA2, 
CA3), dentate gyrus (CA4/DG), and subiculum] and extra-hippocampal structures 
[entorhinal cortex, (ERC) and perirhinal cortex]. Each substructure has different 
computational processing roles contributing to the memory system. Memory 
retrieval occurs upon experiencing environment or internal cue that share specific 
features with a stored memory. These cues are processed in various respective 
neocortical areas, which then send signals to ERC and to DG and then to CA3. 
CA3 is essential for creating the so-called hippocampal index, which distinctly 
records an item or event associated with a particular episode and facilitates 
subsequent retrieval (Nakazawa et al. 2002; Shastri 2002; Teyler and Rudy 
2007). As a result, the neural patterns of activity associated with the original 
event recorded in CA1, subiculum and other neocortical areas are reinstated 
(Shastri 2002; Teyler and Rudy 2007). This reinstatement allows the individual to 
experience the recall of the sensory information (ie.sound, sight smell, taste) that 
were associated with the original event (Gold and Budson 2008). Many groups 
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have reported the alteration in hippocampal shape and surface structure as well 
as atrophy in the medial temporal lobe subregions in AD patients compared to 
age-matched healthy controls (Wang et al. 2006; Barnes et al. 2007; Scher et al. 
2007). ERC (Di Paola et al. 2007), DG (Ohm 2007), CA3 (Adachi et al. 2003) are 
all altered in AD patients.  
Hippocampal atrophy has been the best established biomarker to stage 
the progression of AD pathology in the brain across the entire disease spectrum 
(Jack et al. 2011; Dickerson et al. 2017) among the core biomarkers of AD 
(Dubois et al. 2007; 2010; Albert et al. 2011; McKhann et al. 2011; Sperling et al. 
2011). Burton and colleagues also (2008) reported that MTL/hippocampal 
atrophy is highly accurate diagnostic marker for autopsy confirmed AD.  Their 
ROC analysis for MTL/hippocampal atrophy showed 91% sensitivity and 94% 
specificity for AD diagnosis compared to dementia with Lewy bodies and 
vascular cognitive impairment (Burton et al. 2008). Patients with typical AD 
display atrophy and hypometabolism of the bilateral hippocampus, medial 
temporal lobe, posterior cingulate, precuneus and temporoparietal cortex on 
structural MRI and 18F-fluorodeoxyglucose (FDG)-positron emission tomography 
(PET) brain imaging (Busatto et al. 2003; Warren et al. 2012). 
Alzheimer’s disease is associated with the accumulation of misfolded 
amyloid and tau in the brains of these patients (see below).  Other 
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pathophysiological biomarkers, including PET of brain amyloid, are also utilized 
in corroborating AD diagnosis (McKhann et al. 2011; Blennow et al. 2015). 
Excess amyloid deposition on Pittsburgh compound B (PiB) and other PET 
amyloid radioligands is also seen in AD patients (Pievani et al. 2011; Warren et 
al. 2012). Cerebrospinal fluid (CSF) measurements of tau and amyloid-β (Aβ) are 
also used for diagnosis. Studies have reported an increased level of raised total 
tau and reduced level of Aβ on CSF profile (Shaw et al. 2009).    
 
Section I.C. Pathological hallmark of AD 
Two major pathological hallmarks of AD are plaques, which are composed 
of amyloid-β peptide (Aβ), and neurofibrillary tangles (NFT), which are composed 
of hyperphosphorylated tau protein (P-tau) (Trojanowski and Lee 1999; Blennow 
et al. 2006; 2015). Aβ pathology precedes before tau pathology; the 
accumulation of Aβ leads to accumulation and spread of tau pathology (Braak 
and Braak 1991; Schöll et al. 2016), which in turn results in structural, cognitive 
and function changes in the diseased brain (Bourgeat et al. 2010; Chételat et al. 
2010; Landau et al. 2012; Insel et al. 2016). Braak staging predicts the pattern of 
MTL atrophy. According to Braak staging, tangles begin in the transentorhinal 
cortex of the MTL, which then spreads to hippocampal subfields, and later to 
neocortical areas (Braak and Braak 1991). The pathology underlying AD 
precedes even before the appearance of clinical symptoms.   
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Section I.D. Other cognitive impairments and the associated anatomy in AD 
In addition to memory, deficits in other cognitive domains are seen in 
clinical amnestic AD as well. Deficits in attention, working memory and other 
aspects of executive function are often detected on neuropsychological tests, 
and are associated with atrophy in frontal areas (Baudic et al. 2006). Language 
(Pekkala et al. 2013) and visuospatial abilities (Kasai et al. 2006) are also 
impaired in clinical amnestic AD patients. 
In the language domain, lexical retrieval deficits in discourse serve as an 
early indicator of AD (Pekkala et al. 2013). Lexical retrieval is a multi-step 
process where the corresponding concept of a target word in semantic memory 
is identified and the name that best labels this concept is then selected and 
expressed phonologically or in writing. One way to assess lexical retrieval is a 
picture-naming test, where participants have to name the pictures that are 
shown. Compared to age-matched healthy participants, AD patients perform 
worse on a confrontation naming task 2–3 years before the diagnosis (Chen et 
al. 2001; Mickes et al. 2007). This performance steadily declines in AD patients 
as the disease progresses (Locascio et al. 1995; Salmon et al. 1999). Left middle 
and inferior temporal gyri were associated with naming performance in AD 
patients (Grossman et al. 2004; Graves et al. 2007; Peters et al. 2009b).  
Visuospatial ability is another domain that is impaired in AD patients. In 
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Rey Figure Test, the visuospatial dysfunction is apparent when AD patients are 
copying the Rey Figure; there are some spatial misplacement of geometric 
components of the figure (Kasai et al. 2006). The visuospatial deficit can 
compromise daily activities, such as reading, visuospatial orientation, and motion 
detection, in AD patients reviewed in (Cronin-Golomb and Hof 2004).  The 
performance on the visual tasks declines gradually with the progression of the 
disease (Mendez et al. 1990) and are associated with atrophy in the visual 
association cortex (Mendez et al. 1990) ,Brodmann area 5 of the superior parietal 
lobe (Katz and Rimmer 1989), the parietooccipital junction and the premotor 
areas (Thiyagesh et al. 2009). 
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Section I.E. Clinical trials for AD (any progress?) 
Since the discovery of Alzheimer’s disease in 1906, scientists and 
clinicians from multiple disciplines have worked arduously and collaboratively to 
better understand the pathogenesis of AD by studying molecular, structural, 
functional alterations in the diseased animal models as well as in the patients 
who are clinically diagnosed with AD (Hardy 2006). To determine appropriate 
treatments for AD, cognitive measures have been used traditionally as clinical 
trial endpoints, which are measures of disease outcomes in clinical studies 
(Lawrence et al. 2017). Despite these remarkable efforts for development of 
therapeutic agents, many clinical trials have failed repetitively and there still 
exists the gap between the basic science discovery and clinical application 
(Beach 2017). This has raised many concerns regarding the present propositions 
of disease-modifying agents. There is now converging evidence that the 
pathogenesis of AD gets under way many years before the onset of dementia 
(reviewed in (Sperling et al. 2011)). In 2011, three consensus panels joined to 
better define AD in terms of three clinically-defined stages: (1) presymptomatic or 
preclinical, (2) mild cognitive impairment (MCI), the transition zone between the 
cognitive decline in aging and the cognitive burden of AD, and (3) dementia 
(Albert et al. 2011; McKhann et al. 2011; Sperling et al. 2011). 
In addition to this clinically defined “AD dementia”, which is a well-known 
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common form of dementia by the public, there are other forms of clinical 
syndromes, whose predominant underlying pathology is AD pathology but 
display distinct clinical phenotypical presentations as well as distinct pattern of 
brain atrophy affected (Lam et al. 2013; Dickerson et al. 2017). These cases will 
be referred to as the ‘atypical’ variants of AD, whose age onset is much younger 
(<65 years old) than clinical AD (Dickerson et al. 2017). Because memory seems 
to be relatively spared in these atypical variants of AD compared to the clinical 
AD cases, these atypical cases are misdiagnosed more than half of the times 
(Murray et al. 2011) and are not considered as AD, and hence these cases are 
not eligible for clinical trials for AD. The disadvantage of clinical studies is that the 
diagnoses for the atypical cases are made using clinical criteria and pathologic 
confirmation may not always be available. These variants further demonstrate 
how complex and heterogeneous AD is and poses additional challenges for 
effective treatments targeting the right population. My dissertation focuses on 
studying these atypical variants of AD. My two projects examined whether 
memory was affected in these cases, as seen in the clinical amnestic AD, since 
reports on memory in the atypical cases are variable. Next, if these patients 
appear to have some degree of memory difficulty, my thesis also examined 
which cognitive and anatomical factors contribute the appearance of memory 
difficulty in atypical cases. 
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Section I.F. Variants of AD 
As mentioned above, there are different variant subtypes that are 
associated with AD pathology. Interestingly, many of these variant cases share 
biological features with clinical amnestic AD; the identical plaque and tangle 
pathology found in clinical amnestic AD, which I will refer to as typical AD, are 
also found in these variant clinical subtypes (Dickerson et al. 2017). 
Neuropathologic studies have demonstrated that it is not Aβ plaques that drive 
this heterogeneity within AD syndrome, but rather the distribution of NFTs burden 
and associated neuronal degeneration that forecast the particular clinical 
syndrome (Hof et al. 1989; Dickerson et al. 2017). Murray and colleagues (2011) 
recently developed a system to classify the heterogeneity of neuropathology in 
AD (Murray et al. 2011). Based on the relative density of NFTs in the 
hippocampus and other neocortical areas, AD can be divided into three 
subtypes: typical AD, hippocampal-sparing AD, and limbic-predominant AD 
(Murray et al. 2011; Janocko et al. 2012). NFTs are disproportionately distributed 
in cortical areas with relative sparing of the hippocampus in hippocampal-sparing 
AD, while NFTs distribution follow the pattern of Braak staging scheme in typical 
AD, where hippocampus is mostly affected. There are more NFTs in 
hippocampus, with sparse NFTs in association cortices and little or no NFTs in 
primary sensory-motor cortices in limbic-predominant AD. Age seems to be one 
major factor that influences the topography of neurodegeneration in AD 
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(Dickerson et al. 2017), with younger patients more likely to show 
neurodegeneration more prominently in temporoparietal areas but have less 
prominent NFTs in the MTL (hippocampal-sparing cases) while older patients 
showing more prominent neurodegeneration in the hippocampus and other MTL 
structures than in neocortical areas particularly early in the course of disease 
(“limbic predominant”). 
Typical AD or clinical amnestic AD patients are the cases where memory 
is a predominant factor. On the other hand, hippocampal-sparing AD present with 
different cognitive and anatomic profiles compared to the typical presentation 
seen in clinical AD, and hence sometimes are referred to as ‘atypical’ cases of 
AD. My dissertation focuses on examining hippocampal-sparing variant cases 
of AD. According to the diagnostic criteria for these hippocampal-sparing variant 
of AD cases, memory is relatively spared compared to their prominent deficits in 
other cognitive domains (Warren et al. 2012).  Individuals with hippocampal-
sparing AD may have prominent deficits in language domains, while other may 
have prominent deficits in visuoperceptual domains (Lam et al. 2013; Dickerson 
et al. 2017). The two variants of hippocampal-sparing AD that will be the focus of 
my dissertation are logopenic variant of primary progressive aphasia (lvPPA) 
and posterior cortical atrophy (PCA).  
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Section I.G. Logopenic variant of primary progressive aphasia (lvPPA) 
The language variant of primary progressive aphasia (PPA) often 
associated with AD pathology is the logopenic variant of primary progressive 
aphasia (lvPPA). This is characterized by core features of impaired lexical 
retrieval, and difficulty repeating sentences or phrases (Gorno-Tempini et al. 
2011; Leyton and Hodges 2013; Mesulam et al. 2013). There has been a 
growing interest in lvPPA given that 1) a third of PPA patients have AD as the 
underlying pathology, and 2) lvPPA is an interesting population to examine the 
clinical-anatomical heterogeneity of AD because of its distinct clinical profile and 
distribution of brain atrophy.  
Consensus diagnostic criteria (Gorno-Tempini et al. 2011) require that in 
addition to the core language deficit in confrontation naming and repetition, 
lvPPA patients  must have any of three of the following features: phonological 
errors in spontaneous speech and naming, spared semantic knowledge, spared 
motor speech, and absence of frank agrammatism. LvPPA patients exhibit 
remarkable word-finding difficulties that disrupt the flow of spontaneous 
conversation (Wilson et al. 2010); some authors have described their speech as 
interrupted with sounds such as “mmm,” “uhh,” and “ohh,” as if they are 
searching for the correct target word, or interrupted with repetition of the 
utterance such as “my daughter is, my mother daughter is, picking me up.” The 
naming deficit in lvPPA sometimes is as severe as in the semantic variant of 
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PPA, but naming errors are usually phonological rather than semantic coordinate 
and superordinate errors seen in semantic variant patients. LvPPA patients 
typically have relatively spared semantic knowledge (Leyton et al. 2011; 
Mesulam et al. 2012); lvPPA patients know the properties of the word they are 
meaning to describe (“it’s the Australian one... it hops around” (Leyton and 
Hodges 2013), and performance on naming tasks is improved with phonological 
cues (Rohrer et al. 2010; Leyton et al. 2011; Savage et al. 2013).  
According to the consensus diagnostic criteria, supporting neuroimaging 
of lvPPA patients should display either prominent atrophy in left posterior 
perisylvian/parietal areas on MRI or prominent hypoperfusion or hypometabolism 
in left posterior perisylvian /parietal areas on SPECT or PET (Gorno-Tempini et 
al. 2011). Multiple neuroimaging studies have shown involvement of left temporo- 
parietal junction area, including posterior temporal, supramarginal, and angular 
gyri (Gorno-Tempini et al. 2004; Henry and Gorno-Tempini 2010; Mesulam et al. 
2012; Mesulam and Weintraub 2014; Mesulam et al. 2014b). The damage to 
these areas corresponds to core deficits observed in lvPPA patients. The 
confrontation naming deficit in lvPPA is associated with atrophy in middle 
temporal gyrus and other inferior-posterior parietal areas while the repetition 
deficit is correlated with posterior third of the superior temporal gyrus (Leyton and 
Hodges 2013). The naming deficit in typical AD patients is also associated with 
the inferior-posterior parietal areas (Harasty et al. 1999). This may suggest 
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that the naming deficit in lvPPA and typical AD patients depends on impaired 
lexical retrieval (Hodges et al. 1992; Hodges 1995; Croot et al. 2000).  
The repetition deficit is another cardinal characteristic of lvPPA clinical 
phenotype. LvPPA patients have reduced verbal short-term memory but this 
deficit is secondary to an impairment of the phonological loop, caused by 
damage to the posterior left superior temporal gyrus (Archeson et al., 2011; 
Baldon et al., 2012). Many studies have shown reduced performance in digit 
span and tasks that requires a high demand on short-term memory resources 
correlating to atrophy in posterior left superior temporal gyrus (Amici et al. 2007; 
Leff et al. 2009; Acheson et al. 2011; Richardson et al. 2011; Baldo et al. 2012). 
While typical AD patients have reduced verbal short-term memory, the 
mechanism underlying this deficit also may be due to an executive control deficit 
caused by atrophy in frontal regions (Peters et al. 2009a; Huntley and Howard 
2010). 
Episodic memory should be relatively spared according to the diagnostic 
criteria for lvPPA. However, evaluations of verbal episodic memory have been 
inconsistent in lvPPA (Josephs et al. 2013; Rohrer et al. 2013; Flanagan et al. 
2014; Piguet et al. 2015; Ramanan et al. 2016). This is frequently assessed with 
verbal delayed free recall. However, recall may be confounded by the lexical 
retrieval deficit in lvPPA. While visual memory has been reported to be spared in 
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lvPPA (Weintraub et al. 2013), this would not explain the verbal episodic memory 
deficit that has been reported in lvPPA. Hence, the question of interest is whether 
verbal episodic memory is affected, measured by verbal delayed free recall 
performance, and if so, which factors might explain this appearance of deficit. 
How would lvPPA patients perform on the verbal recognition memory test, which 
does not require the process of lexical retrieval? One study has reported that 
lvPPA patients have comparable performance on verbal recognition memory 
compared to healthy controls (Ramanan et al. 2016). Review of the lvPPA 
literature is not very clear on this issue of verbal episodic memory performance in 
lvPPA. No other study has examined in detail the relationship between lexical 
retrieval and verbal episodic memory, assessed via verbal delayed free recall. 
This gap in knowledge can lead to more inconsistent reports on verbal episodic 
memory performance in lvPPA literature. It is, therefore, the hope of my research 
to fill this gap (more details in RATIONALE SECTION on page 23).  
The clinical boundary between lvPPA and typical AD presentations can 
sometimes be blurry due to the language deficits that can be observed in typical 
AD (Leyton and Hodges 2013). There are some overlapping cognitive 
characteristics between lvPPA and AD. Language impairment, including lexical 
retrieval deficit, is observed in both lvPPA (Gorno-Tempini et al. 2004; Henry and 
Gorno-Tempini 2010; Gorno-Tempini et al. 2011; Mesulam 2013; Mesulam et al. 
2014a) and typical AD (Grossman et al. 2004; Pekkala et al. 2013). While 
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repetition difficulty is a necessary feature of lvPPA (Gorno-Tempini et al. 2011), 
AD patients also can exhibit repetition difficulty (2014). In some cases, lvPPA 
patients are impaired on verbal episodic memory (Flanagan et al. 2014; 
Ramanan et al. 2016). Our clinical cohort of lvPPA also showed some degree of 
impairment on verbal delayed recall task (Win et al. 2017). At a first glance, the 
two cohorts thus can present with similar clinical characteristics and can be 
confusing in terms of diagnosis.  
A majority of cases of lvPPA are associated with AD pathology. However, 
the distribution of pathological changes and genetic risk factors are different 
between lvPPA patients and typical AD patients. Compared to typical AD, lvPPA 
patients have a higher proportion of NFT pathologic burden in the left perisylvian 
language cortices than typical AD patients (Gefen et al. 2012). Consistent with 
the distinct clinical phenotypes of typical AD and lvPPA, different genetic risk 
factors may play a role in lvPPA compared to typical AD. Apolipoprotein ε4 
(APOE4) polymorphism, which is linked to typical AD, is less common in lvPPA 
(Wolk et al. 2010; Rogalski et al. 2011b). 
 
Section I.H. Posterior cortical atrophy (PCA) 
Posterior cortical atrophy (PCA) is a neurodegenerative condition, 
characterized by prominent visual perceptual-spatial deficits. This syndrome was 
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first described in 1988 when Benson et al. [1] reported five patients with 
prominent visual complaints and who all exhibited both Balint’s  syndrome 
(oculomotor apraxia, simultanagnosia, optic ataxia) and Gerstmann’s syndrome 
(agraphia, acalculia, finger anomia, right-left disorientation). Early diagnosis of 
PCA is a major challenge and often delayed owing to its misleading presentation 
with visual complaints, which lead patients to consult an ophthalmologist at first 
(Tang-Wai 2004). Based on neuropsychological examination, PCA patients 
display alexia, Balint’s syndrome, Gerstmann’s syndrome, prosopagnosia, or 
environmental agnosia (Borruat 2013). The complaints associated with the 
visuospatial deficit include blurred vision, lack of sharpness, difficulty walking on 
uneven ground, difficulty evaluating distances when driving, inaccurately 
grasping objects under visual guidance (Crutch et al. 2012; Vighetto 2013; 
Crutch et al. 2013b). Additional complaints associated with visuoperceptual 
deficits include difficulty recognizing faces, landmarks, or objects (Crutch et al. 
2012; Vighetto 2013; Crutch et al. 2013b).   
The visuospatial dysfunction results from damage to the occipitoparietal 
pathway, also known as the dorsal (‘where’) pathway of visual information (Biotti 
et al., 2012). In contrast, visuoperceptual dysfunction results from damage to the 
occipitotemporal pathway or ventral (‘what’) pathway, which mediates recognition 
of forms and colors that account in part for the various forms of visual agnosia 
(Borruat 2013). Lehmann and colleagues (2011) examined basic visual 
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processing in 21 PCA patients, which was assessed with six tests: form 
detection, form coherence, form discrimination, color discrimination, motion 
coherence, and point localization; and higher-order visual functions. Performance 
was correlated with cortical thickness. All PCA patients were impaired in at least 
one basic visual function test, and 81% of these patients were impaired on at 
least 3/6 tests. These patients were categorized based on dorsal stream and 
ventral stream dysfunction: patients with visuospatial difficulties had thinner 
occipitoparietal areas while patients with visuoperceptual difficulties had thinner 
occipitotemporal areas.  
While a small number of PCA cases is associated with dementia with 
Lewy Bodies, corticobasal degeneration (CBD), or rarely, Creutzfeldt–Jakob 
disease (Renner et al., 2004; Tang-Wai et al., 2004), majority of cases of PCA 
are associated with AD pathology. Just like in lvPPA patients, PCA patients have 
a different distribution of pathological changes and genetic risk factors compared 
to typical AD. Compared to typical AD, PCA patients have fewer plaques and 
NFTs in the prefrontal cortex and hippocampus, while greater burden of plaques 
and NFTs in the occipitoparietal areas and occipitotemporal junction is observed 
(Hof et al., 1997; Tang-Wai et al., 2004). Genetically, ApoE 4 allele does not 
seem to be a risk factor for PCA, while it is strongly associated with typical AD 
(Schott et al., 2006; Snowden et al., 2007; Van der Flier et al., 2006).  
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There are many proposed diagnostic criteria for PCA outlined by several 
centers over the past decade (Mendez et al. 2002; Tang-Wai 2004), but 
consensus criteria were just recently developed this year by a number of 
clinicians and researchers from multiple international centers in an effort to 
establish a consensus opinion regarding the PCA syndrome (Crutch et al. 2017). 
According to these international consensus diagnostic criteria (Crutch et al. 
2017), PCA patients must present with at least three of the following features: 
space perception deficit,  simultanagnosia,  object perception deficit, 
constructional dyspraxia, environmental agnosia, oculomotor apraxia, dressing 
apraxia, optic ataxia, alexia, left/right disorientation, acalculia, limb apraxia (not 
limb-kinetic), apperceptive prosopagnosia, agraphia,  homonymous visual field 
defect, or finger agnosia. In addition, PCA patients must have relative sparing of 
memory, speech and nonvisual language, executive functions, behavior and 
personality. Neuroimaging must display prominent occipitoparietal or 
occipitotemporal atrophy on MRI or hypometabolism/hypoperfusion on FDG-
PET/ SPECT. 
Reports on examination of memory in PCA are not very systematic. 
Neuropsychological studies of PCA patients reported sparing of memory in PCA 
(Renner et al. 2004; Charles and Hillis 2005; Migliaccio et al. 2009b; Crutch et al. 
2012; Borruat 2013; Crutch et al. 2013a; Ossenkoppele et al. 2015) but these 
studies use verbal recall task to measure ‘memory’. As mentioned earlier, 
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episodic memory can be examined in two modalities, verbal and visual. The 
careful examination of visual episodic memory is crucially important given the 
diagnostic criteria requirement of relative sparing of ‘memory.’ However, all these 
neuropsychological studies (Renner et al. 2004; Charles and Hillis 2005; 
Migliaccio et al. 2009b; Crutch et al. 2012; Borruat 2013; Crutch et al. 2013a; 
Ossenkoppele et al. 2015) reported the deficit of visuospatial skills in PCA but 
failed to report the visual component of episodic memory. Visual episodic 
memory in PCA may be impaired especially due to the inability to encode the 
visual materials that the patients are asked to remember. Indeed, a case study 
report of a PCA patient has displayed the poor performance of Rey Recall test 
(Kennedy et al. 2012). But no study has examined the visuospatial and 
visuoperceptual factors contributing to visual episodic memory performance in 
PCA, and there still remains a gap in knowledge in the field. My research 
addressed this concern and aimed to fill this gap (more details in Section I.I).  
  
		
	
21	
Section I.I. Research focus: rationale for this research 
AD pathology in these atypical variant cases may be “hippocampal-
sparing” (Murray et al. 2011; Janocko et al. 2012; Lam et al. 2013; Wolk 2013) 
and thus may not begin in the MTL as in clinical amnestic cases of AD (Braak 
and Braak 1991). Indeed, the diagnostic criteria for these atypical variant cases 
required relatively preserved episodic memory. However, there have been 
inconsistent reports on episodic memory sparing and the involvement of MTL 
structures, including the hippocampus, in lvPPA and PCA. The overarching 
theme of my thesis is to examine 1) whether these atypical cases of AD have 
episodic memory difficulty (verbal modality in lvPPA and visual modality in PCA), 
and if so, 2) what brain areas are responsible for this difficulty. I hypothesize that 
episodic memory difficulty in atypical AD cases is mild, and is often associated 
with non-memory components of performance, such as difficulty retrieving a list 
of words during verbal free recall or difficulty encoding visuospatial materials that 
must be recalled. Moreover, I hypothesize that this pattern of performance on 
memory tasks is associated with disease in other, non-MTL brain regions. This 
would be consistent with the hypothesis that not all AD histopathology begins in 
the MTL, and these hippocampal-sparing conditions suggest that additional 
mechanisms must be considered in the genesis of spreading pathology in AD.   
Prominent verbal and nonverbal memory loss and visuospatial impairment 
are exclusionary criteria for PPA (Gorno-Tempini et al. 2011). However, 
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evaluations of verbal episodic memory have been inconsistent in lvPPA (Rohrer 
et al. 2013; Flanagan et al. 2014). This is frequently assessed with delayed 
verbal free recall, where participants name a list of recalled words after a delay 
period. However, poor verbal recall may be confounded by the lexical retrieval 
deficit in lvPPA. Thus, their failure to retrieve the phonological word form of a 
target word can easily be misinterpreted as an inability to recall this target word 
on the memory paradigm. One group has assessed both verbal and non-verbal 
episodic memory in PPA patients, and shown verbal retrieval failures compared 
to relatively successful visual memory (Weintraub et al. 2013).  However, this 
group studied a mixture of PPA variants (including agrammatic, logopenic, and 
semantic).  Moreover, this study did not clarify whether delayed verbal free recall 
deficits in lvPPA specifically are due to the true episodic memory difficulties, 
mediated by MTL/hippocampus or limited lexical retrieval.  
Reports of hippocampal atrophy in lvPPA also have been inconsistent 
(Gorno-Tempini et al. 2011; Josephs et al. 2013; Mesulam 2013), despite a 
statistical association of lvPPA with Alzheimer’s disease (AD) pathology 
(Grossman, 2010; Gianinni et al, 2017).  Likewise, the distribution of pathology in 
lvPPA has been unclear (Hu et al. 2010).  Some have reported no observable 
difference in neurofibrillary tangle (NFT) density in hippocampus between lvPPA 
and clinical AD (Josephs et al. 2013), while others have reported minimal NFT 
pathology in the hippocampus of lvPPA (Gefen et al. 2012). These 
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inconsistent reports on lvPPA cases may be due in part to the clinical 
heterogeneity of lvPPA. Recent findings (Sajjadi et al. 2014; Mesulam et al. 
2014a; Leyton et al. 2015) showed that not all lvPPA cases are uniform: some 
displayed only lexical retrieval deficit with predominant atrophy in posterior-
inferior temporal-parietal areas, while others displayed additional repetition deficit 
with prominent atrophy in left superior temporal gyrus. The third subgroup of 
lvPPA displayed mild deficits in single word comprehension with atrophy 
extending to the medial aspect of temporal cortex (Leyton et al. 2015).  These 
reports still did not address the question of the appearance of verbal episodic 
memory performance and the status of the involvement of hippocampus. No 
group has evaluated the role of lexical retrieval in verbal episodic memory in 
lvPPA, nor evaluated the anatomical basis for apparent verbal episodic memory 
difficulty in lvPPA. Here, my research examined more closely the role of a lexical 
retrieval deficit in verbal episodic memory performance of lvPPA, and gray matter 
(GM) atrophy associated with these deficits in left lateral and medial temporal 
lobe (MTL) including hippocampus.  
Studies of neurodegenerative patients and fMRI studies of healthy adults 
have associated lexical retrieval with left middle temporal gyrus (Grossman et al. 
2004; DeLeon et al. 2007; Baldo et al. 2013). Since both lvPPA (Gorno-Tempini 
et al. 2011; Leyton et al. 2015) and clinical AD patients (Grossman et al. 2004; 
Pekkala et al. 2013) have lexical retrieval difficulty, we predicted that left 
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middle temporal gyrus would be associated with lexical retrieval in both lvPPA 
and clinical AD. We also hypothesized that, if a lexical retrieval deficit interferes 
with delayed free recall in lvPPA, left middle temporal gyrus atrophy would be 
associated with delayed free recall performance. By comparison, we predicted 
that delayed verbal free recall performance in clinical typical AD would be 
associated with hippocampal atrophy. Because the hippocampus is comprised of 
different subfields, it is possible that subfields within the hippocampus in lvPPA 
are differentially affected. Thus, there may be selective atrophy of a hippocampal 
subfield in lvPPA that is too small to see because of the limited spatial resolution 
of traditional MRI, and this may interfere with verbal episodic memory in lvPPA.  
Traditional T1 imaging cannot detect subtle changes in hippocampal subfields 
(Yushkevich et al. 2014). To overcome this issue, we used high in-plane 
resolution T2 imaging to assess hippocampal subfields.  This fine-grained 
analysis allowed us to examine whether delayed free recall in lvPPA and clinical 
AD could be due in part to selective atrophy of hippocampal subfields.   
As in lvPPA, criteria for PCA requires relatively spared memory. It is 
difficult to assess the visual episodic memory in PCA given their visuoperceptual 
and visuospatial difficulty. PCA patients do perform poorly on visual episodic 
memory tasks, such as recall of the Rey Complex Figure (Crutch et al. 2012). 
However, reports of visual episodic memory difficulty in PCA are highly variable 
(Renner et al. 2004; Kas et al. 2011; Ossenkoppele et al. 2015). Unlike 
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clinical typical AD cases, PCA patients have minimal atrophy in the 
hippocampus(Lam et al. 2013). One study has reported the deformation of 
hippocampal shape in PCA (Manning et al. 2015). It is unclear, whether 
hippocampus is involved in visual episodic memory performance.  
The disease in PCA at the early stage may begin in parietal areas, 
including precuneus. Precuneus is another structure that is widely implicated in 
episodic memory retrieval (reviewed in (Cavanna and Trimble 2006)). Many 
studies have reported the activation of precuneus during the episodic memory 
retrieval of highly imageable pairs of associates (Fletcher et al. 1995), old/new 
effect or remember/know judgment in a recognition memory paradigm (Addis et 
al. 2007; Dörfel et al. 2009), as well a retrieval of past episodes and imagining 
the future (Schacter and Addis 2007). Indeed, the role of precuneus in episodic 
memory is not surprising given that precuneus is anatomically and functionally 
connected to the medial temporal lobe, including the hippocampus (Takahashi et 
al. 2008). 
Given the underlying AD pathology, it is unclear whether the visual 
episodic memory deficit seen in PCA patients is affected directly by their 
precuneus disease or hippocampal atrophy. Here, we examined both visual 
perceptual and visual episodic memory function in PCA and related these 
performances to precuneus atrophy. Because most PCA cases are associated 
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with AD pathology, I could not rule out selective atrophy of a hippocampal 
subfield in PCA that is too small to see because of the limited spatial resolution of 
traditional MRI, and this may interfere with episodic memory in PCA.  Thus, I was 
interested to examine whether MTL subfield atrophy in PCA patients could 
explain a visual episodic memory deficit.  I used fine-grained high resolution 
imaging that allowed us to quantify the subfields within the MTL. We also 
included typical amnestic AD patients as lesion control for a comparative study. 
We hypothesized that PCA patients, unlike typical AD, have visual episodic 
memory difficulty, and this may be due in part to their precuneus disease, and 
not due to MTL/hippocampal atrophy. 
To summarize, the overarching hypotheses for episodic memory 
performance in atypical variants of AD (lvPPA and PCA) cases are: 1) Episodic 
memory in atypical AD may due in part to deficits in other cognitive domains; and 
2) Episodic memory in atypical AD may be associated with disease in other, non-
MTL brain regions.  To test these hypotheses, standard neuropsychological tests 
that tapped into respective cognitive deficits were employed. Next, we utilized T1 
brain imaging to define the gray matter areas that were atrophied in patients 
compared to demographically matched (age, gender, education) elderly 
participants. The atrophy of gray matter areas was then related to the 
performance on neuropsychological tests in lvPPA and PCA. Region of interest 
of analyses were also employed to examine whether whole hippocampus 
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was affected. We took a step further to examine whether hippocampal 
subregions were differentially involved in atypical AD. As mentioned above, the 
MTL and hippocampus is a complex structure that is comprised of multiple 
subregions. While hippocampal atrophy may not be detected when performing 
whole brain analyses and region of interest analyses, it is possible that 
hippocampal subregions are differentially affected. Traditional T1 brain imaging 
may not be ideal for detecting differential involvement of MTL and hippocampal 
subregions. Collaborating with Paul Yushkevich, we were able to utilize a high-
resolution T2 imaging sequence that optimized the visualization of hippocampal 
subregions and allowed me to examine quantitatively whether hippocampal 
subregions and extrahippocampal structures are differentially affected in these 
atypical AD cases.  
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CHAPTER II. Project 1: Examine the neuroanatomical basis of verbal 
episodic memory in lvPPA 
Section II.A. INTRODUCTION 
Logopenic variant primary progressive aphasia (lvPPA) is a 
neurodegenerative condition that is a form of primary progressive aphasia (PPA) 
characterized by core deficits in repetition and lexical retrieval, a process of 
linking the semantic representations of objects, actions, thoughts and the like to 
their corresponding phonological word forms (Gorno-Tempini et al. 2011; Leyton 
and Hodges 2013; Mesulam et al. 2013). According to the published diagnostic 
criteria (Gorno-Tempini et al. 2011), verbal episodic memory should be spared. 
However, evaluations of verbal episodic memory have been inconsistent in 
lvPPA (Rohrer et al. 2013; Flanagan et al. 2014).  This is frequently assessed 
with delayed free recall, where participants name a list of recalled words after a 
delay period. However, recall may be confounded by the lexical retrieval deficit in 
lvPPA. Thus, their failure to retrieve the respective phonological word form of the 
target word can easily be confused with their inability to recall this target word on 
the memory paradigm. One group has assessed both verbal and non-verbal 
episodic memory in PPA patients, and shown verbal retrieval failures compared 
to relatively successful visual memory (Weintraub et al. 2013).  However, this 
group studied a mixture of PPA variants (including agrammatic, logopenic, and 
semantic).  Moreover, this study did not clarify whether delayed verbal free recall 
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deficits in lvPPA specifically are due to hippocampal-mediated episodic memory 
difficulties or limited lexical retrieval.  
Reports of hippocampal atrophy in lvPPA also have been inconsistent 
(Gorno-Tempini et al. 2011; Josephs et al. 2013; Mesulam 2013), despite a 
statistical association of lvPPA with Alzheimer’s disease (AD) pathology 
(Grossman 2010).  Likewise, the distribution of pathology in lvPPA has been 
unclear (Hu et al. 2010).  Some have reported no observable difference in 
neurofibrillary tangle (NFT) density in hippocampus between lvPPA and clinical 
AD (Josephs et al. 2013), while others have reported minimal NFT pathology in 
the hippocampus of lvPPA (Gefen et al. 2012). These inconsistent reports on 
lvPPA cases may be due in part to the clinical heterogeneity of lvPPA. Recent 
findings (Sajjadi et al. 2014; Mesulam et al. 2014a; Leyton et al. 2015) showed 
that not all lvPPA cases are uniform: some displayed only lexical retrieval deficit 
with predominant atrophy in posterior-inferior temporal-parietal areas, while 
others displayed additional repetition deficit with prominent atrophy in left 
superior temporal gyrus. The third subgroup of lvPPA displayed mild deficits in 
single word comprehension with atrophy extending to the medial aspect of 
temporal cortex (Leyton et al. 2015).  
No group has evaluated the role of lexical retrieval in verbal episodic 
memory in lvPPA, nor evaluated the anatomical basis for episodic memory 
difficulty in lvPPA. Here, we examined more closely the role of a lexical retrieval 
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deficit in verbal episodic memory performance of lvPPA, and gray matter (GM) 
atrophy associated with these deficits in left lateral and medial temporal lobe 
(MTL) including hippocampus. Studies of neurodegenerative patients and fMRI 
studies of healthy adults have associated lexical retrieval with left middle 
temporal gyrus (Grossman et al. 2004; DeLeon et al. 2007; Baldo et al. 2013). 
Since both lvPPA (Gorno-Tempini et al. 2011; Leyton et al. 2015) and clinical AD 
patients (Grossman et al. 2004; Pekkala et al. 2013) have lexical retrieval 
difficulty, we predicted that left middle temporal gyrus would be associated with 
lexical retrieval in both lvPPA and clinical AD. We also hypothesized that, if a 
lexical retrieval deficit interferes with delayed free recall in lvPPA, left middle 
temporal gyrus atrophy would be associated with delayed free recall 
performance. By comparison, we predicted that delayed free recall performance 
in clinical AD would be associated with hippocampal atrophy. Because the 
hippocampus is comprised of different subfields, it is possible that subfields 
within the hippocampus in lvPPA are differentially affected. Traditional T1 
imaging cannot detect subtle changes in hippocampal subfields (Yushkevich et 
al. 2014). To overcome this issue, we used high in-plane resolution T2 imaging to 
assess hippocampal subfields.  This fine-grained analysis allowed us to examine 
whether delayed free recall in lvPPA and clinical AD could be due in part to 
selective atrophy of hippocampal subfields.   
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Section II.B. METHODS  
Participants  
We studied 38 right-handed native English-speakers with lvPPA (n=12) or 
clinical AD (n=26), and 16 healthy controls [Mini-Mental State Examination 
(MMSE; (Folstein et al. 1975a) > 27] with comparable gender [X2=0.08; p>0.05], 
age [F(2,51)=1.24; p>0.05], and education [F(2,51)=0.49; p>0.05] recruited from 
the Frontotemporal Degeneration Center at the University of Pennsylvania. 
lvPPA and AD patients were matched in MMSE [U=94.5, Z=-1.95, p>0.05] and 
disease duration [U=153.50, Z=-0.08, p>0.05]. Because we were interested in 
whether lexical retrieval modulates verbal episodic memory, Boston Naming Test  
(BNT; (Williams et al. 1989) performance in lvPPA and AD was matched 
[U=111.00, Z=-1.43, p>0.05]. Diagnoses were established using published 
criteria for lvPPA (Gorno-Tempini et al. 2011) and clinical AD (McKhann et al. 
2011) by board-certified neurologists (DJI, MG) based on a mental status 
examination. Clinically, lvPPA patients displayed word-finding and repetition 
problems while clinical AD patients displayed episodic memory difficulties. 
Exclusionary criteria included vascular disease, structural brain abnormalities 
such as hydrocephalus, medical diseases interfering with cognition, and primary 
psychiatric disorders. Nine of twelve lvPPA patients had cerebrospinal fluid 
(CSF) data: 8 with CSF ABeta42<192 pg/ml [mean (S.D.) = 127.38 (27.43)] that 
is consistent with likely AD pathology and 1 without this criterion (ABeta42>192 
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pg/ml: 357 pg/ml). Fourteen of 26 clinical AD patients had available CSF data 
with ABeta42<192 pg/ml [mean (S.D.) = 124.14 (20.67)].  
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Behavioral methods 
Neuropsychological testing included a 30-item BNT ((Williams et al. 1989)  
to assess lexical retrieval; the delayed free recall component of the Philadelphia 
Verbal Learning Test (PVLT; (Libon et al. 2011a), a 9-word list-learning task  
(drawn from 3 semantic categories {tools, fruits, furniture} with 5 learning trials, 
immediate recall and delayed recall probes, and recognition with equal numbers 
of foil types (semantic, interference, unrelated) to assess verbal episodic 
memory; and forward digit span (FDS; (Wechsler 1997) to assess repetition. To 
minimize the lexical retrieval component of verbal episodic memory, we also 
assessed the recognition component of PVLT (Libon et al. 2011a) using d-prime, 
the difference between the z-transforms of hit rate and false alarm rate, to 
account for the false positive alarm rate. Shapiro-Wilk test showed that 
demographic variables were normally distributed (p>0.05) but neuropsychological 
variables were not (p<0.05). Hence, neuropsychological variables were assessed 
using non-parametric tests including X2, Mann-Whitney U, and Kruskal-Wallis.  
Standard protocol approvals, registrations, and patient consents. All 
subjects completed a written informed consent procedure in accordance with the 
Declaration of Helsinki and approved by the institutional review board (IRB) of 
the University of Pennsylvania. The study was approved by the University of 
Pennsylvania’s IRB.  
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Imaging 
We included subsets of lvPPA (n=10; 8 with AD-CSF and 1 without) and 
AD (n=26; 14 with AD-CSF and 1 without) patients who had available high-
resolution T1 MRI scans, and an independent group of 17 healthy matched 
controls (gender: X2=1.27,p>0.05; age: X2=0.38, p>0.05; education: X2=1.00; 
p>0.05]. These participants underwent a structural T1-weighted, 3-dimensional, 
spoiled gradient-echo sequence, which was obtained on a Siemens 3.0T Trio 
scanner with an 8-channel head coil with sequence parameters of TR = 1620 ms, 
TE = 3 ms, flip angle = 15_, matrix = 192 _ 256, slice thickness = 1 mm, and in-
plane resolution = 1 x1 mm. The images were normalized to a standard space 
and segmented using the Advanced Normalization Tools (ANTs) 
(http://www.picsl.upenn.edu/ANTS/) PipeDream interface 
(http://sourceforge.net/projects/neuropipedream/) (Tustison et al., 2014). 
Reasons for exclusion included health and safety (e.g., metallic implants, 
shrapnel, claustrophobia), intercurrent illness, scheduling and transportation 
difficulty. Imaging was acquired within 6 months (µ=2.6 months, σ=2.6) of 
behavioral data. We used Advanced Normalization Tools (ANTs), a state-of-the-
art pipeline, for all image processing, as described elsewhere (McMillan and 
Wolk 2016). 
T1 Whole-Brain Imaging Analysis. Non-parametric permutation-based imaging 
analyses were performed with threshold-free cluster enhancement (TFCE) 
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(Smith and Nichols 2009) using the randomise tool in FSL 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki). GM density was compared in lvPPA relative to 
controls. A t-test analysis was run with 10,000 permutations that is equivalent to 
a contrast corrected for multiple comparisons. The analyses were restricted to 
voxels containing GM using an explicit mask generated from the average GM 
probability map of all groups. We report clusters that survived a threshold of 
p<0.005 (uncorrected with TFCE), and contained a minimum of 50 adjacent 
voxels.  
To relate behavioral performance to significant GM atrophy, we used the 
randomise tool of FSL to compute regression analyses between lvPPA patients' 
performance on a target task and GM density in regions of the brain showing GM 
atrophy relative to controls. Permutations were run exhaustively up to a 
maximum of 10,000 for each analysis. We reported clusters surviving a height 
threshold of p<0.05 uncorrected with TFCE and a minimum of 10 adjacent 
voxels.  We used a very liberal statistical threshold purposefully to see if there is 
any possibility of a regression between episodic memory functioning and GM 
density in MTL of lvPPA. 
Peak Voxel Region of Interest (ROI). Because we were interested to assess 
whether the region of left middle temporal gyrus identified in lvPPA was also 
implicated in AD performance, we extracted the statistically-significant peak voxel 
from the left middle temporal gyrus cluster identified in lvPPA (see below) and 
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used this peak voxel as our label for left middle temporal gyrus in AD. GM 
density at this peak voxel in left middle temporal gyrus was calculated in AD 
patients and controls, and Spearman correlation assessed an association 
between GM density of left middle temporal gyrus and BNT and delayed free 
recall in AD.  
T2 Medial Temporal Lobe Imaging. To determine whether lvPPA patients had 
subtle hippocampal atrophy that could have impacted their verbal episodic 
memory, we examined the subset of patients who had high-resolution T2-
weighted scan with the 8-channel coil (7 lvPPA {6 with AD-CSF, 1 without}, 19 
AD (11 with AD-CSF, 1 without), and 17 demographically-matched controls. The 
parameters of the T2 are the following: TR/TE: 5310/68 ms, echo train length 15, 
18.3 ms echo spacing, 150 flip angle, 0% phase oversampling, 0.4 3 0.4 mm2 in 
plane resolution, 2 mm slice thickness, 30 interleaved slices with 0.6 mm gap, 
acquisition time 7:12 min. Images of each subject were labeled using the 
Automatic Segmentation of Hippocampus Subfields (ASHS) software 
(Yushkevich et al. 2014). This method utilizes a training and a segmentation 
pipeline that combines a multi-atlas label fusion (Wang et al. 2013) and a 
learning-based error correction module to produce a fully automated 
segmentation of Cornu Ammonis (CA), dentate gyrus (DG), and subiculum 
subfields along the entire length of the hippocampal formation, as well as 
segmentation of extrahippocampal structures, entorhinal (ERC) and perirhinal 
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cortices (BA35 and BA36). Briefly, candidate segmentations of a subject’s T2-
MRI were obtained using high-dimensional mapping to multiple manually labeled 
atlas images, and then fused into a consensus segmentation, taking into account 
the similarity between a subject’s image and atlas images. Patterns of systematic 
segmentation errors are learned a priori using training data, and are corrected in 
a further post-processing step, to generate the final segmentation. Reliability of 
automated labeling for these subfields is generally high, as reported (Yushkevich 
et al. 2014), but CA2/3 were excluded since their segmentation was not reliable. 
Volumetric measures of the hippocampal subfields and thickness of 
extrahippocampal subfields were extracted for quantitative comparisons across 
cohorts. Thickness was used for extrahippocampal subfields since these 
subfields were not segmented throughout the entire anterior-posterior axis of 
MTL and we needed to normalize the volume by the number of segmented 
slices. Spearman correlation analyses were performed to relate MTL subfield 
atrophy to BNT as well as delayed free recall. 
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Section II.C. RESULTS 
Behavioral Analysis  
Compared to controls, worse MMSE was observed in lvPPA [U=18.00, 
Z=-3.83, p<0.001] and AD [U=2.00, Z=-5.42, p<0.001]. However, lvPPA and AD 
patients were matched in MMSE (Folstein et al. 1975b) [U=94.5, Z=-1.95, 
p>0.05] and disease duration [U=153.50, Z=-0.08, p>0.05]. Consistent with their 
clinical phenotype, lvPPA patients were more impaired on BNT [U=47.00, Z=-
2.31, p<0.05] and FDS [U=21.50, Z=-3.54, p<0.001] than controls. FDS also was 
worse in lvPPA than AD (U=73.00, Z=-2.66, p<0.05). Though recognition 
memory was intact in lvPPA relative to controls [U=66.50, Z=-1.49, p>0.05], 
these patients exhibited worse delayed free recall relative to controls [U=39.00, 
Z=-2.69, p<0.01].  A correlation analysis revealed that BNT was associated with 
delayed free recall in lvPPA (rs=0.721, p=0.019) but BNT was not associated 
with recognition memory (rs=0.302, p=0.34). Intact verbal recognition memory 
suggested relatively preserved verbal episodic memory in lvPPA, and a common 
cognitive mechanism underlying impairments in lexical retrieval and delayed free 
recall in lvPPA.  
Relative to controls, AD performed worse on BNT [U=52.50, Z=-4.05, 
p<0.001], delayed free recall [U=22.00, Z=-4.91, p<0.001] and recognition 
memory [U=78.50, Z=-3.39, p<0.005] but had intact FDS [U=133.00, Z=-1.68, 
p>0.05]. Relative to lvPPA, AD had worse delayed free recall [U=70.50, Z=-2.76, 
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p<0.01] and recognition memory (U=89.5, Z=-2.10, p<0.05). Unlike lvPPA, there 
was no association between delayed free recall and BNT in AD (r=0.110, 
p=0.591).  
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Imaging Analysis 
Whole-Brain Imaging. We examined whether there was a shared 
neuroanatomic substrate for BNT and delayed free recall in lvPPA. Compared to 
controls, lvPPA displayed GM atrophy only in left middle temporal gyrus (Fig.1), 
while the hippocampus was spared. Regression was used to relate behavioral 
performance to GM atrophy in lvPPA; decreased performance on both BNT 
(Fig.1, Panel A) and delayed free recall (Fig.1, Panel B) was related to left middle 
temporal gyrus atrophy.  
Region of Interest Analysis.  GM density at the peak voxel of left middle 
temporal gyrus cluster associated with BNT and delayed free recall in the whole-
brain regression analysis described above was extracted for every participant of 
the cohort. GM density of this peak voxel was reduced in lvPPA compared to 
controls [U=61.00, Z=-2.01, p<0.05] and in AD compared to controls [U=114.00, 
Z=-2.52, p<0.05].  Reduced GM density at this left middle temporal gyrus voxel in 
AD was associated with decreased performance on BNT (r=0.537, p=0.006) but 
not with delayed free recall (p>0.05).  
MTL subfield Imaging. We examined whether hippocampal (CA1, DG, 
and subiculum) and extra-hippocampal subfields (ERC, BA35, and BA36) were 
differentially affected in lvPPA (Fig. 2, Panel A). Consistent with whole-brain 
regression results, there was no significant difference in hippocampal and 
extrahippocampal subfields between lvPPA and controls. However, AD patients 
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had differential MTL subfield atrophy compared to controls.  This included 
bilateral CA1 and DG (Fig. 2. Panel B; left CA1 [p<0.001], right CA1 [p<0.001], 
left DG [p<0.005], right DG [p<0.005). AD also showed atrophy in extra-
hippocampal subfields (Fig2, Panel B), including left ERC [p<0.05] and right 
BA35 [p<0.01]).   
Spearman correlation was used to assess an association between MTL 
subfields and behavioral performance. Neither BNT nor delayed free recall was 
associated with MTL subfields in lvPPA.  In AD, both left CA1 [rs=0.543,p=0.016] 
and right CA1 [rs=0.473,p=0.022] were associated with delayed free recall, but 
not BNT (p>0.05).  
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Section II.D. DISCUSSION 
The status of verbal episodic memory performance in lvPPA is unclear. In 
this study, we aimed to elucidate whether the core language deficit in lexical 
retrieval in lvPPA interferes with their verbal episodic memory functioning and 
whether hippocampus disease also contributes to episodic memory difficulty, 
given the statistical likelihood of underlying AD pathology (Josephs et al. 2008; 
Grossman 2010; Mesulam et al. 2012). We found impaired lexical retrieval in 
lvPPA, and this correlated with their delayed verbal free recall performance. This 
was mediated by a common neural substrate in left middle temporal gyrus, but 
did not appear to be associated with MTL. Although CSF analyses indicated that 
likely AD pathology was present in a majority of lvPPA cases, detailed 
examination of hippocampal subfields failed to reveal any atrophy in lvPPA 
relative to controls. By comparison, clinical AD patients had atrophy in MTL 
subfields, which was associated with verbal episodic memory difficulty, while 
BNT was associated with left middle temporal gyrus. These findings are 
consistent with other reports of quantitative pathologic evidence of a 
hippocampal-sparing aphasic variant with AD pathology, which has 
disproportionate amount of NFT in cortical areas with relative sparing of the 
hippocampus (Janocko et al. 2012).  The hippocampal-sparing variant of AD with 
primarily progressive aphasia due to prominent neocortical AD pathology 
accumulation is different from typical amnestic AD, where the NFT distribution 
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follows the Braak staging pattern (Braak and Braak 1991), of significant NFT 
burden in medial temporal lobe structures, including the hippocampus, relative to 
NFT distribution in the cortex. These different clinical and pathological variants of 
AD call to question the hypothesis that pathology originates in the MTL of all 
patients with AD pathology.   
According to the 2011 criteria for PPA (Gorno-Tempini et al. 2011), 
patients are diagnosed with lvPPA if they exhibit impaired lexical retrieval and 
repetition as their primary deficit, with relatively preserved episodic memory. 
Given that lvPPA is a form of aphasia, most studies have focused on the 
language domain and have not evaluated the role of memory performance in the 
difficulties associated with diagnosing lvPPA.  Evaluating verbal episodic memory 
performance in lvPPA may pose a challenge. Indeed, reports of verbal episodic 
memory performance in lvPPA have been inconsistent, with some reporting 
impaired memory (Flanagan et al. 2014; Piguet et al. 2015; Ramanan et al. 2016) 
and one study observing equally impaired verbal episodic memory and 
recognition memory in AD and lvPPA patients who also had visual memory 
difficulty (Ramanan et al. 2016), while others found no deficit (Weintraub et al. 
2013; Mesulam et al. 2014b).  
Verbal episodic memory is typically tested using delayed free recall, which 
requires lexical retrieval and production, and therefore verbal episodic memory 
can be confounded by the lexical retrieval deficit observed in lvPPA.  However, 
		
	
44	
previous work has not indicated whether verbal episodic memory difficulty is 
associated with impaired lexical retrieval. We found verbal episodic memory 
difficulty in lvPPA and that this deficit was correlated with their impaired lexical 
retrieval, raising the possibility that lexical retrieval difficulty may underlie in part 
the verbal episodic memory deficit that is reported at times in lvPPA. We also 
found that our lvPPA cohort had preserved verbal recognition memory, and we 
hypothesize that this was because this form of verbal episodic memory testing 
does not require lexical retrieval and production. While it is possible that 
successful recognition memory performance was due in part to the fact that this 
is an easier task than delayed free recall, it is noteworthy that the clinical AD 
patients matched the lvPPA patients in MMSE, yet lvPPA patients were 
significantly less impaired in their recognition memory than AD.  Another group 
reported similar findings, where PPA patients were impaired on verbal recall, but 
their performance on verbal recognition memory was near ceiling compared to 
controls (Weintraub et al. 2013). Additional work is needed to evaluate episodic 
memory performance in lvPPA.   
Our findings associated lexical retrieval difficulty in lvPPA with atrophy of 
left middle temporal gyrus. This area has been widely implicated in lexical 
retrieval in lvPPA (Henry and Gorno-Tempini 2010; Leyton and Hodges 2013; 
Mesulam et al. 2013; 2014a) as well as AD (Harasty et al. 1999; Grossman et al. 
2004; Apostolova et al. 2008) and stroke (DeLeon et al. 2007; Indefrey 2011). 
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Moreover, delayed free recall performance in lvPPA was related to the same 
area of left middle temporal gyrus, underlining the contribution of impaired lexical 
retrieval to the verbal episodic memory deficits of lvPPA.  Moreover, there was 
no hippocampal atrophy in lvPPA that could have explained any memory 
difficulty.  Our study also found that lexical retrieval difficulty in AD is associated 
with the same cluster of left middle temporal gyrus that was atrophied in lvPPA. 
Unlike lvPPA, delayed free recall performance in AD was not related to left 
middle temporal gyrus.   
Despite the presence of likely AD pathology in most of our lvPPA cohort, 
detailed analysis reveal no observable changes in hippocampal and 
extrahippocampal subfields compared to controls, while AD patients showed 
hippocampal subfield atrophy that was associated with their verbal episodic 
memory deficit. Involvement of the hippocampus in the neuroimaging and 
pathological literature in lvPPA has been inconsistent. One report described 
greater NFT burden in language-related areas and throughout the left 
hemisphere than entorhinal cortices in lvPPA, and that NFT deposition is greater 
in the left peri-Sylvian language cortices than typical AD patients (Gefen et al. 
2012). Others reported no observable difference in NFT density in the 
hippocampus in lvPPA compared to AD, consistent with their imaging result, 
although NFT density ratio in temporoparietal areas relative to hippocampus is 
higher in lvPPA (Josephs et al. 2013).  MMSE of lvPPA reported in this paper 
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was in the moderately impaired range (14.3±7.7), reflecting patients with 
considerably more cognitive impairment than our cohort, and this may explain in 
part the discrepancy with findings of the present study where patients had milder 
cognitive impairment (MMSE: 25.67±3.2). Other sources of discrepancy in the 
literature may be due in part to the relatively small sample sizes of lvPPA, 
different severity and disease duration of patient groups, and pathological 
observations typically obtained many years after the clinical phenotype has been 
ascertained. Nevertheless, paralleling our findings, a functional connectivity study 
demonstrated that the language network encompassing left posterior temporal 
areas is more affected in lvPPA than in AD, while the ventral default mode 
network associated with episodic memory was affected in AD more than lvPPA 
(Whitwell et al. 2015). Longitudinal imaging studies of lvPPA patients have 
suggested that the atrophy initially involving the left temporoparietal region 
subsequently spreads to include other left hemisphere regions (Rohrer et al. 
2010; Rogalski et al. 2011a), although the presence of likely AD pathology was 
assessed only in a small number of cases. Hippocampal-sparing variant of AD 
cases has been identified as one of the three AD subtypes [amnestic AD (75% 
out of 889 cases), hippocampal sparing (11%), and limbic predominant (14%)] in 
autopsy series of patients with AD pathology (Murray et al. 2011). Our findings, 
together with these suggestive studies, raise the possibility of a variant of AD 
where pathology does not originate in the MTL, and suggest that the lvPPA 
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phenotype may be a marker of this variant. Findings such as these warrant more 
detailed examination of hypotheses concerned with spreading pathology in 
neurodegenerative diseases such as AD.  
Some limitations must be considered when interpreting our data. First, 
atrophy in our lvPPA cohort was limited to left middle temporal gyrus. Other 
neuroimaging studies have shown a greater extent of atrophy encompassing left 
temporal-parietal junction (Gorno-Tempini et al. 2004; Migliaccio et al. 2009a). 
When using a more liberal threshold (p <0.01, uncorrected), we also observed a 
similar atrophy pattern in left temporal and parietal areas area consistent with 
other neuroimaging studies. However, we did not observe left MTL atrophy even 
at this more liberal threshold in our lvPPA cohort. Second, while our cohorts were 
carefully matched, our sample size was relatively small.  Larger cohorts of lvPPA 
patients are needed to assess these brain-behavior relationships more reliably.  
Although our patients had a typical phenotype of lvPPA that is statistically 
associated with AD pathology, two of our cases did not have CSF available that 
could have provided biomarker evidence of AD. Additional longitudinal studies 
would be helpful in resolving discrepancies concerning disease severity across 
studies. Lastly, our lvPPA cohort was relatively young, as was our matched AD 
group. Caution thus must be exercised in generalizing our findings to late-onset 
patients with lvPPA and AD.  
With these caveats in mind, we conclude that lexical retrieval difficulty in 
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lvPPA interferes with verbal episodic memory functioning, and left middle 
temporal gyrus disease may be contributing to this common cognitive 
mechanism. No hippocampal atrophy was evident despite the presence of likely 
AD pathology in lvPPA. Verbal delayed free recall thus can be confounded by 
lexical retrieval difficulty in lvPPA, and this confound may be circumvented in part 
with recognition memory testing.  Although both our AD and lvPPA cohorts were 
cognitively comparable, the cognitive and anatomical profile of lvPPA is distinct 
from AD, where the apparent memory deficit was mediated by hippocampal 
disease and was not modulated by lexical retrieval difficulty or left middle 
temporal gyrus atrophy. These distinctions suggest that lvPPA may be a marker 
for an atypical, hippocampal-sparing variant of AD pathology that may not 
originate in the MTL.  
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Section II.E. Tables/Figures 
 
Table 1. Mean (standard deviation) demographic & clinical features of the 
cohorts 
Measure 
lvPPA 
(n=12) 
AD 
(n=26) 
Healthy Seniors 
(n=16) 
Demographic features of the cohorts 
 
 
Gender (Male/Female) 5/7 14/12 7/9 
Age, years 63.10 (8.80) 64.73 (7.78) 69.00 (9.13) 
Education, years 16.08 (4.12) 15.19 (2.68) 15.94 (2.49) 
Disease Duration, years 3.75 (2.38) 3.73 (2.00) N/A 
Neuropsychological performance 
 
 
Mini Mental State Exam 
(max=30) 
25.67 (3.20) 23.69 (2.19) 29.63 (0.72) 
Forward digit span (# 
digits) 
4.67 (1.07) 5.88 (1.45) 6.68 (1.20) 
Boston Naming Test 
(max=30) 
23.75 (6.77) 22.85 (5.11) 28.19 (1.97) 
Recognition Memory (d-
prime) 
2.77 (0.57) 1.88 (1.04) 3.04 (0.24) 
Delayed free recall 
(max=9) 
4.58 (3.15) 1.73 (2.51) 7.69 (1.30) 
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Figure 1. Whole Brain Atrophy and Regression in lvPPA. Pattern of atrophy 
of gray matter (GM), shown in blue (surface rendering and coronal slice), in 
lvPPA compared to controls. Atrophy was found only in the left hemisphere; 
these areas include middle temporal and parietal areas, significant at p < 0.005 
(uncorrected with threshold-free cluster enhancement). A) Decreased 
performance on BNT related to GM atrophy is shown in red. B) Decreased 
performance on delayed free recall related to GM is shown in red. Left middle 
temporal gyrus regression for both BNT and delayed free recall was shown in the 
coronal slice. 
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Figure 2. A: A representative segmentation of left MTL subfields in one of the 
participants in each group (healthy senior, lvPPA, AD) shown in a coronal view. 
B: Profile of volume of left and right hippocampal and extrahippocampal subfields 
across cohorts. **p<0.01,  ***p<0.001. Cornu Ammonis (CA), dentate gyrus (DG), 
subiculum (SUB), entorhinal (ERC) and perirhinal cortices (BA35 and BA36).  
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CHAPTER III. Project 2: Examine the neuroanatomical basis of visual 
episodic memory in PCA 
Section III.A. INTRODUCTION 
Posterior cortical atrophy (PCA) is a neurodegenerative disorder 
characterized by a progressive decline in visuospatial and visuoperceptual 
processing (Crutch et al. 2017).  Consistent with the clinical phenotype, the 
predominant site of atrophy in PCA involves areas of the cerebrum that are 
important for visual perceptual-spatial processing, including occipital and 
posterior temporal and parietal cortices as well as precuneus. According to the 
most recent international consensus criteria, episodic memory is relatively spared 
(Crutch et al. 2017).  This is an important consideration since clinical-pathological 
studies of PCA have shown that the overwhelming majority of reported cases 
have microscopic abnormalities most consistent with histopathology features of 
Alzheimer’s disease.  Most studies examining the neuropsychological 
characteristics of PCA corroborated this criterion of relatively spared episodic 
memory compared to their predominant deficit in the visuoperceptual and 
visuospatial domain (Renner et al. 2004; Charles and Hillis 2005; Migliaccio et al. 
2009b; Kas et al. 2011; Crutch et al. 2012; Borruat 2013; Crutch et al. 2013a; 
Ossenkoppele et al. 2015), suggesting that PCA is a non-amnestic variant of AD.  
These studies have reported on verbal recall performance in PCA patients, which 
is relatively preserved, but visual episodic memory performance such as recall of 
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a complex visual geometric figure like the Rey Figure has not been reported 
frequently or examined carefully in PCA patients due to their difficulty in visual 
domain.  Indeed, PCA patients appear to perform poorly on visual episodic 
memory tasks (Kennedy et al. 2012). Although this case study examined 
visuoperceptual and visuospatial functioning in PCA, Kennedy and colleagues 
(2012) did not take into account of visuoperceptual and visuospatial difficulty 
while assessing the visual memory. It is, therefore, unclear whether visual 
episodic memory deficits in PCA are due to impairment in episodic memory or to 
their impairment in visuoperceptual and visuospatial processing. 
Although most PCA cases have AD as their underlying pathology, PCA 
differs from typical AD cases with amnestic memory difficulty because PCA 
patients are said to have minimal atrophy in the hippocampus (Lehmann et al. 
2011; Crutch et al. 2012; Ossenkoppele et al. 2015).  The hippocampus and the 
medial temporal lobe (MTL) are the structures most commonly associated with 
episodic memory difficulty and hypothesized to be the site of pathological onset 
of AD (Braak and Braak 1991).  Most MRI assessments of the hippocampus and 
MTL use whole-brain imaging, but this may miss atrophy in a hippocampal 
subfield that may be interfering with memory functioning.  Precuneus is another 
structure that is widely implicated in episodic memory, in addition to its role in 
visuospatial and visuoperceptual processing (reviewed Cavanna and Trimble, 
2006; (Trimble and Cavanna 2008)). Kas and colleagues (2011) reported that 
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perfusion of precuneus is correlated with behavioral phenotype of PCA 
syndrome, including apraxia, acalculia, ocular apraxia, optic apraxia and Balint’s 
syndrome (Kas et al. 2011). Precuneus contributes to oculomotor guidance and 
spatial control of motor activity (Cavanna and Trimble 2006). In addition to this 
role, studies have reported the activation of precuneus in healthy subjects during 
recognition memory (Addis et al. 2007; Dörfel et al. 2009) and retrieval of past 
episodes (Schacter and Addis 2007). In typical AD patients, precuneus is one of 
the earliest regions of hypoperfusion (Asllani et al. 2007; Langbaum et al. 2010; 
Miners et al. 2016) . Indeed, its role in episodic memory may not be surprising 
given that precuneus is anatomically and functionally connected to the MTL 
including the hippocampus  (Takahashi et al. 2008).  From this perspective, it is 
unclear whether precuneus is contributing to visual perceptual-spatial difficulties, 
memory deficits, or both in PCA. 
In the present study, we examined both visual perceptual-spatial and 
visual episodic memory function in PCA, and examined whether performance is 
related to precuneus and hippocampal atrophy, including hippocampal subfields.  
We hypothesized that PCA patients have visual perceptual-spatial deficits as well 
as visual episodic memory difficulty that are associated in part with precuneus 
disease, and unlike typical AD, their memory difficulty is less associated with 
hippocampal atrophy. To examine the involvement of precuneus and 
hippocampus in visual perceptual-spatial and visual episodic memory functioning 
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in PCA, we also performed region of interest analyses and general linear model 
analyses to assess whether precuneus and hippocampus were related to visual 
episodic memory performance. Because the MTL is a complex structure 
consisting of multiple subregions, we also used high resolution T2 imaging to 
quantitatively examine whether hippocampal and extrahippocampal subfields 
were affected.  
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Section III.B. METHODS  
Participants 
We studied 42 right-handed native English-speakers with PCA (n=13), 
typical AD (n=17), and 12 healthy seniors (MMSE > 27) recruited from the Penn 
Frontotemporal Degeneration Center of the Department of Neurology at the 
University of Pennsylvania.  Both our PCA and AD cohorts were seen by board-
certified neurologists (DI, MG): diagnosis for our PCA cohort was established by 
criteria suggested by Crutch et al (2017) and were consistent with previous 
descriptions of PCA (Tang-Wai, 2004; McMonagle et al., 2006; Crutch 2012); 
diagnosis for our AD cohort is consistent with criteria for mild amnestic AD 
(McKhann et al., 2011). Clinically, PCA patients displayed visuoperceptual and 
visuospatial problems, including core features of Balint’s syndrome such as 
difficulty locating objects in space, difficulty with body-part relationships, and 
difficulty with dressing and performing other spatially-mediated tasks, while AD 
patients displayed episodic memory difficulties.  A consensus evaluation was 
used to confirm clinical diagnosis, based on a semi-structured neurologic history, 
a complete neurologic examination, and a detailed mental status assessment.  
CSF examination in PCA (n=9 have available CSF data) and AD (n=17) was 
consistent with underlying AD pathology in both groups as 100% of PCA patients 
and 100% of AD patients had CSF level of beta-amyloid1-42 <192 pg/ml.  As 
summarized in Table 1, groups were matched for gender [X2 (2)=0.522; p>0.05], 
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age [F(2,39)=2.18; p p>0.05], and education [F(2,39)=0.38; p p>0.05].  Disease 
duration between patient groups was matched [U=101.00, Z=-0.41, p>0.05].  
Exclusionary criteria included evidence of vascular disease or structural brain 
abnormalities such as hydrocephalus, but MRI was not used for diagnostic 
purposes.  Patients were also excluded on the basis of medical diseases 
interfering with cognition and primary psychiatric disorders. 
 
Behavioral methods 
Participants had neuropsychological testing that included mini-mental 
state examination (MMSE; Folstein et al., 1975) to assess the disease severity; 
modified Rey Complex Figure (Lezak et al. 2012) from Philadelphia Brief 
Assessment of Cognition ((Libon et al. 2011b); total score=12 instead of 36 using 
a specific scoring algorithm) recall one minute after their copy to assess visual 
episodic memory. To account for visuoperceptual difficulty on visual episodic 
memory performance, we calculated the percentage of modified Rey Recall 
performance in each individual based on the elements presented in the 
individual’s modified Rey Copy performance (recall score divided by copy score; 
referred to as percentage of copied recall in Table 1). To assess verbal episodic 
memory, we used verbal learning and memory from Philadelphia Brief 
Assessment of Cognition (Libon et al. 2011b), which is a six-word list 
administered over three trials.Verbal delayed free recall for this list was assessed 
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after a 1–2-minute filled delay. Between-group differences in neuropsychological 
variables were assessed using X2 tests, t-tests, analysis of variance (ANOVA), 
Mann-Whitney U-Test and Tukey test, as appropriate.    
 
Standard protocol approvals, registrations, and patient consents. All 
subjects completed a written informed consent procedure in accordance with the 
Declaration of Helsinki and approved by the institutional review board of the 
University of Pennsylvania. 
 
Imaging methods.  
For imaging analyses, all 13 PCA and 17 AD patients had high-resolution T1 MRI 
scans, and imaging in controls was obtained from an independent group of 16 
healthy seniors with comparable gender [X2 (2)=0.51; p=.98], age [F(2,42)=1.82; 
p=0.174], and education [F(2,42)=0.15; p=0.87].  These participants underwent a 
structural T1-weighted, 3-dimensional, spoiled gradient-echo sequence, which 
was obtained on a Siemens 3.0T Trio scanner with an 8-channel head coil with 
sequence parameters of TR = 1620 ms, TE = 3 ms, flip angle = 15°, matrix = 192 
x 256, slice thickness = 1 mm, and in-plane resolution = 1 x1 mm. The images 
were normalized to a standard space and segmented using the Advanced 
Normalization Tools (ANTs) (http://www.picsl.upenn.edu/ANTS/) PipeDream 
interface (http://sourceforge.net/projects/neuropipedream/) (Tustison et al. 2014). 
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Imaging was acquired within 6 months (µ=2.6 months, σ=2.6) of behavioral data.  
T1 Whole Brain Imaging Analysis. Non-parametric permutation-based 
imaging analyses were performed using the randomise tool in FSL 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki) with TFCE (Smith and Nichols 2009).  Gray 
matter (GM) density was compared in PCA and AD relative to healthy seniors.  A 
t-test analysis was run with 10,000 permutations that is equivalent to a contrast 
corrected for multiple comparisons.  The analyses were restricted to voxels 
containing GM using an explicit mask generated from the average GM probability 
map of all groups.  We report clusters that survived a threshold of p<0.005 (FWE 
corrected), and contained a minimum of 50 adjacent voxels.  
To relate behavioral performance to regions of significant GM disease, we 
used the randomise tool of FSL with TFCE to compute regression analyses 
between patients' performance on a target task and GM density in regions of the 
brain showing GM atrophy relative to healthy seniors. Permutations were run 
exhaustively up to a maximum of 10,000 for each analysis. We reported clusters 
surviving a height threshold of p<0.05 (uncorrected) and a minimum of 10 
adjacent voxels.  
Region of Interest Analysis. Thirty normal aging brains from the OASIS 
dataset (Marcus et al. 2007) underwent labeling using MindBoggle protocol (Arno 
Klein 2012). After applying ANTs joint label fusion, which is a weighted voting 
based label fusion technique (Wang et al. 2013), on the 30 labeled brains, an 
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anatomically defined template space label set containing 98 cortical and 15 
subcortical GM regions of interest (ROIs) were generated. The label set was then 
warped from the template space to each individual’s native space in our PCA 
cohort and masked by the individual’s GM image to create the individual’s native 
label set. GM volumes of each ROI in the individual’s native label set were then 
calculated. Because we were interested in the involvement of precuneus and 
hippocampus in visual memory, bilateral precuneus and hippocampus (4 ROIs, 
Fig 2) were extracted from the label set. We then performed a regression 
analysis with PCA patients’ behavioral scores of interest and GM volume in these 
ROI regions, while covarying for their intracranial volume. A significant positive 
regression would suggest that the involvement of the each ROI is predicted by 
the respective behavioral performance.  
T2 Medial Temporal Lobe Thickness Analysis. We sought to determine 
whether PCA patients had differential MTL and hippocampal subfield atrophy that 
could have impacted their visual episodic memory. Therefore we examined MTL 
subfields using high-resolution T2-MRI images {TR/TE: 5310/68 ms, echo train 
length 15, 18.3 ms echo spacing, 15° flip angle, 0% phase oversampling, 0.4 x 
0.4 mm2 in plane resolution, 2 mm slice thickness, 30 interleaved slices with 0.6 
mm gap, acquisition time 7:12 min} that were labeled using the Automatic 
Segmentation of Hippocampus Subfields (ASHS) software package (Yushkevich 
et al. 2014). We examined the subset of patients who had high-resolution 
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T2 MRI scans of the medial temporal lobe (7 PCA, 12 AD, and 16 healthy seniors 
who were demographically matched to the entire cohort and to each other) 
obtained in the same scan session. Briefly, this method utilizes a training pipeline 
and a segmentation pipeline that combines a multi-atlas label fusion (Wang et al. 
2013) and a learning-based error correction module to produce a fully automated 
segmentation of Cornu Ammonis (CA), dentate gyrus (DG), and subiculum 
subfields along the entire length of the hippocampal formation, as well as 
segmentation of extrahippocampal structures, including entorhinal (ERC) and 
perirhinal (BA35 and BA36) and parahippocampal cortices (PHC).  Candidate 
segmentations of a subject’s T2-MRI were obtained using high-dimensional 
mapping to multiple manually labeled atlas images, and then fused into a 
consensus segmentation, taking into account the similarity between a subject’s 
image and atlas images. Patterns of systematic segmentation errors are learned 
a priori using training data, and are corrected in a further post-processing step, to 
generate the final segmentation.  Reliability of automated labeling for these 
subfields is high, as reported (Yushkevich et al. 2014). CA2/3 were not included 
in our analyses since their segmentation was not reliable.  Thickness measures 
of subfields were extracted by establishing point-wise correspondence between 
automatic segmentation for quantitative comparisons across cohorts (FWE 
corrected). Thickness was used for extra-hippocampal subfields since these 
subfields were not segmented throughout the entire anterior-posterior axis of 
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MTL and we needed to normalize the volume by the number of slices 
contributing to the analysis. Pearson correlation analyses were performed to 
relate MTL subfield atrophy to Rey recall performance. 
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Section III.C. RESULTS 
Behavioral Analysis. Table 1 summarizes the behavior profile and 
results of participants in our study. Compared to controls, worse MMSE was 
observed in PCA [U=13.50, Z=-3.57, p<0.001] and AD [U=0.00, Z=-4.55, 
p<0.001] compared to controls.  AD patients were more impaired on MMSE  
[U=60.00, Z=-2.12, p<0.05] compared to PCA patients, although we found no 
correlation between MMSE and other cognitive measures.  Consistent with their 
clinical phenotype, PCA patients were more impaired on modified Rey Copy 
[U=30.00, Z=-3.16, p=0.002] and modified Rey Recall [U=2.00, Z=-4.19, 
p<0.001] than controls. AD patients were also more impaired on modified Rey 
Copy [U=18.00, Z=-4.00, p<0.001] and modified Rey Recall [U=4.50, Z=-4.40, 
p<0.001] than controls. Between PCA and AD patients, there was no significant 
difference in modified Rey Copy [U=95.50, Z=-0.64, p>0.05] or modified Rey 
Recall [U=101.50, Z=-0.40, p>0.05] performance. To reduce the potential 
confound presented by the challenge of evaluating visual episodic memory 
performance in an individual who has difficulty perceiving the stimulus, we also 
examined visual recall as a percent of each participant’s visual copy 
performance. Compared to controls, lower percentage of copied recall was 
observed in PCA [U=14.00, Z=-3.53, p<0.001] and AD [U=4.50, Z=-4.41, 
p<0.001]. There was no significant difference in percentage of copied recall 
[U=99.50, Z=-0.49, p>0.05] between PCA and AD patients. AD patients may be 
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at a disadvantage for performing modified Rey Recall since they may not be able 
to use verbally-mediated recall strategy to recall the geometric shapes due to 
their verbal episodic memory difficulty. 
T1 Imaging Analysis. Whole brain imaging showed that PCA, relative to 
healthy seniors, has significant atrophy in occipitotemporal and parietal cortices 
(OTPC), including bilateral precuneus and inferior parietal gyri (FIg. 1A); AD had 
a widespread atrophy relative to healthy seniors in OTPC, including bilateral 
precuneus, inferior parietal gyri, middle temporal gyri, as well as MTL regions 
including bilateral hippocampi (FIg. 1B).  
Regression analyses in PCA showed that Rey recall in PCA is related to 
bilateral precuneus and angular gyrus (Fig 1C). In AD, Rey recall was related to 
bilateral hippocampus, right middle temporal gyrus, and right precuneus (Fig 1D).  
To account for patients’ visuoperceptual difficulty in their performance on visual 
episodic memory, we also performed a regression analysis on copied recall 
(percent of Rey Recall) performance in PCA and AD. This regression analysis 
showed that Rey Recall performance, after taking account of visuoperceptual 
difficulty, in PCA was associated with areas in OTPC, including right precuneus 
(Fig 1E) while Rey Recall performance, after taking account of visuoperceptual 
difficulty, in AD was associated with hippocampus and right MTG (Fig 1F). This 
result showed that precuneus and other parietal areas significantly modulate 
visual episodic memory performance in PCA even after taking into account for 
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their visuoperceptual difficulty.  
Region of Interest Analysis. Since both hippocampus and precuneus 
have been implicated in memory retrieval, we used hippocampus and precuneus 
regions of interest (Fig 2) to further examine the plausible contributions of each of 
these regions in visual episodic memory performance, assessed by Rey Recall, 
in PCA. We then used general linear model (GLM) to demonstrate whether the 
involvement of precuneus and hippocampus was predicted by Rey Recall 
performance. Rey Recall predicted the right precuneus (Table 2), but not the left 
precuneus. Rey Recall was not associated with the hippocampus bilaterally 
(Table 2).  
Medial Temporal Lobe Subfield Imaging Analysis. We examined 
whether hippocampal (CA1, DG, and subiculum) and extra-hippocampal 
subfields (ERC, BA35, and BA36) were differentially affected in PCA.  MTL 
subfields were comparable between PCA and controls (p>0.05). However, AD 
patients, compared to the controls, had thinner left subiculum (p<0..001), left DG 
(p<0.001), left BA35 (<0.001), left PHC (p<0.01), right DG (p<0.001), right ERC 
(p<0.01), right PHC (p<0.001). Compared to PCA, AD patients had thinner left 
PHC (p<0.01) and left BA35 (p<0.01). Regional thickness of significant MTL 
subfields across the cohorts is illustrated in Fig 3.  We related thinning of MTL 
subfields in AD patients to their performance on Rey recall and found that left 
subiculum (r=0.8, p=0.002) and right DG (r=0.7, p=0.009) were associated with 
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visual episodic memory. There was no association between visual episodic 
memory and MTL subfields in PCA patients. 
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Section III.D. DISCUSSION 
The presence and anatomic basis for visual episodic memory difficulty in 
PCA is unclear. In this study, we aimed to elucidate whether the visuoperceptual 
deficit in PCA interferes with their visual episodic memory functioning and 
whether MTL and hippocampal disease also contributes to this appearance on 
visual episodic memory difficulty, given the statistical likelihood of underlying AD 
pathology (Ossenkoppele et al. 2015). We found a visuoperceptual deficit, 
evident by Rey Copy, as well as visual episodic memory difficulty, assessed by 
Rey Recall, in PCA.    
According to the most recent 2017 international consensus criteria for 
PCA (Crutch et al. 2017), patients are diagnosed with PCA if they exhibit 
impaired visuoperceptual and visuospatial deficit as their primary deficit, with 
relatively preserved episodic memory. Given that PCA patients have impairment 
in the visuoperceptual domain, most studies have not evaluated visual memory 
performance, resulting in difficulties diagnosing PCA.  This is because of the 
potential confound presented by the challenge of evaluating visual episodic 
memory performance in an individual who has difficulty perceiving the stimulus 
that must be recalled. PCA patients in fact performed poorly on the Rey Copy 
task compared to healthy seniors.  In the present study, we addressed this 
challenge by examining visual recall as a percent of each patient’s visual copy 
performance.  Using this measure, we found poor visual memory recall 
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performance in PCA.  These findings lead us to conclude that patients with PCA 
have visual episodic memory difficulty.   
It is noteworthy that, consistent with other reports, we found that verbal 
recall was relatively spared in PCA patients (p>0.05).  One way to circumvent the 
potential confounds associated with assessments of visual memory in PCA has 
been the assessment of verbal episodic memory.  However, this does not 
address the issue of the basis for visual episodic memory difficulty found in PCA.  
We addressed this issue in the present study by relating memory performance to 
the anatomic distribution of atrophy in PCA.  We found that performance on 
visual memory measures was related to brain regions in the parietal areas, 
including bilateral precuneus. Even after taking into account of their 
visuoperceptual difficulty, we still found that precuneus was associated with Rey 
Recall performance. The ROI analysis of precuneus also revealed converging 
findings, where Rey Recall performance predicted the involvement of right 
precuneus but not the hippocampus. Along with our study, several functional 
imaging studies have shown the activation of precuneus in episodic memory 
retrieval tasks (Rugg et al. 2002; Cabeza and Nyberg 2006). Earlier studies have 
demonstrated that precuneus is involved in retrieval that depends on mental 
imagery (Shallice et al. 1994; Fletcher et al. 1995) as well as retrieval 
independent of imagery  (Krause et al. 1999; Schmidt 2002).  
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Importantly, neither visuoperceptual nor visual episodic memory 
performance appeared to be associated with MTL or hippocampus in PCA.  
Although CSF analyses indicated that likely AD pathology was present in a 
majority of PCA cases, detailed examination of MTL subfields failed to reveal any 
atrophy in PCA relative to controls. PCA findings thus are consistent with other 
reports of quantitative pathologic evidence of a hippocampal-sparing variant with 
AD pathology, which has disproportionate amount of NFT in occipitotemporal and 
parietal areas with relative sparing of the hippocampus (Janocko et al. 2012). As 
Murray and colleagues have reported, hippocampal-sparing variant of AD cases 
has been identified as one of the three AD subtypes [amnestic AD (75% out of 
889 cases), hippocampal sparing (11%), and limbic predominant (14%)] in 
autopsy series of patients with AD pathology (Murray et al. 2011). The 
hippocampal-sparing variant of AD with visuoperceptual impairment due to 
prominent neocortical AD pathology accumulation is different from typical 
amnestic AD, where the NFT distribution follows the Braak staging pattern (Braak 
and Braak 1991), of significant NFT burden in MTL structures, including the 
hippocampus, relative to NFT distribution in the cortex. Our findings, together 
with these suggestive studies, raise the possibility of a variant of AD where 
pathology does not originate in the MTL, and suggest that the PCA phenotype 
may be a marker of this variant. Findings such as these warrant more detailed 
examination of hypotheses concerned with spreading pathology in 
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neurodegenerative diseases such as AD.  
Some limitations must be considered when interpreting our data. First, 
atrophy in our PCA cohort using the whole brain T1 imaging analyses was 
defined using a conservative threshold (FWE corrected p < 0.005) and 
hippocampus was not one of the areas that was affected at this threshold. When 
using a much more liberal threshold (p <0.01, FWE corrected), we were able to 
observe some hippocampal atrophy. However, ROI analysis of the hippocampus 
as well as the fine-grained T2 imaging analysis of MTL subfields did not show 
evidence of hippocampal atrophy or evidence of hippocampal involvement in the 
visual episodic memory deficit observed in our PCA cohort. Second, while our 
cohorts were carefully matched demographically as well as the patient groups 
were matched for the disease duration, our sample size was relatively small.  
Larger cohorts of PCA patients are needed to assess these brain-behavior 
relationships more reliably.  Although our patients had a typical phenotype of 
PCA that is statistically associated with AD pathology, four of our cases did not 
have CSF that was consistent with biomarker evidence of AD pathology, opening 
the possibility that another pathologic condition may be underlying the typical 
PCA syndrome we observed in our cohort. Additional longitudinal studies would 
be helpful in determining whether some of these PCA patients evolve over time 
to a clinical presentation that is more typical of amnestic AD. Lastly, although our 
PCA cohort was age-matched to our AD group, MMSE was worse in our AD 
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cohort than PCA. Caution thus must be exercised in generalizing our findings to 
late-onset patients with PCA and AD.  
With these caveats in mind, we conclude that PCA patients appear to 
have visual episodic memory difficulty. Visual perceptual-spatial difficulty is a 
prominent clinical feature of PCA, and despite attempts to control for these 
perceptual-spatial deficits, the visual memory deficit in PCA remained statistically 
robust.  Both visual perceptual-spatial and visual memory deficits were related to 
atrophy in occipitoparietal areas, including bilateral precuneus. However, no 
hippocampal atrophy was evident in PCA despite the presence of likely AD 
pathology.  These findings suggest that PCA may be a marker for an atypical, 
hippocampal-sparing variant of AD, and implicate precuneus in visual episodic 
memory functioning.  The clinical-anatomical profile of PCA is distinct from AD, 
where the visual memory deficit was related to MTL and hippocampal atrophy 
seen in these patients.  
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Section III.E. Tables/Figures 
Table 1. Mean (standard deviation) demographic & clinical features of the 
cohorts 
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Figure 1. Whole Brain Atrophy and Regression in PCA. Pattern of atrophy of 
gray matter (GM), shown in blue (coronal slice), in patients compared to controls, 
significant at p < 0.005 (FWE corrected with threshold-free cluster enhancement). 
A) PCA<ELD, atrophy was found in occipitotemporal and parietal areas, including 
the precuneus, but there was no hippocampal atrophy. B) AD<ELD, atrophy was 
found in occipitotemporal and parietal areas, including the hippocampus and 
precuneus. Decreased performance on Rey Recall related to GM atrophy is 
shown in pink for PCA (C) and AD (D). Decreased performance on copied recall 
(percent of Rey Recall; recall corrected for copy performance) related to GM 
atrophy is shown in pink for PCA (E) and AD (F). uncorrected p<0.05, k >= 10 
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Figure 2. Mind-boogle label of precuneus and hippocampus 
 
 
Table 2. General Linear Model predicting the involvement of precuneus and 
hippocampus. ICV: intracranial volume 
Anatomic 
ROI 
Hemisphere 
Rey Recall + ICV 
R
2
 p value 
Precuneus 
R 0.6342 0.0065 
L  -  - 
Hippocampus 
R  - -  
L  -  - 
 
  
		
	
76	
Figure 3. Regional Thickness Analysis of MTL Subfields in patients.  
MRG: merged surface rendering for all the MTL subfields except dentate gyrus 
(DG). 
 
A. B. 
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CHAPTER IV. DISCUSSION/FUTURE DIRECTIONS 
Section IV.A. Summaries of my research and potential shortcomings 
Episodic memory is the most prominent deficit in the early stage of clinical 
amnestic AD. This deficit is reflected by shrinkage of the MTL structures, 
including the hippocampus. According to Braak staging, tangles, a key 
pathological markers of AD, begin in the transentorhinal cortex of the MTL, which 
then spreads to hippocampal subfields, and later to neocortical areas (Braak and 
Braak 1991). Interestingly, many of the atypical variants of AD appear to share 
the same histopathological features with clinical amnestic AD, but clinical 
diagnostic criteria require episodic memory to be relatively preserved early in the 
disease course of these atypical cases. The two kinds of atypical variants of AD 
that I focused on here and included in my thesis projects are logopenic variant 
of Primary Progressive Aphasia (lvPPA), also known as the language variant 
of AD and posterior cortical atrophy (PCA), also known as the visual variant 
of AD. Despite AD pathology, the cognitive and anatomical profile of atypical 
variants of AD cases, particularly lvPPA and PCA, are distinct from the 
presentation of clinical amnestic AD. The reports on episodic memory 
performance and MTL involvement in lvPPA and PCA are inconsistent. My 
dissertation examined whether (1) the atypical cases of AD have episodic 
memory difficulty, and if so, 2) what brain areas are responsible for this difficulty. 
The central hypothesis is that impaired performance on measures of episodic 
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memory difficulty in atypical AD cases is due in part to non-memory components 
of the task, such as lexical retrieval and visual perception, and that this pattern of 
performance is associated in part with disease in other, non-MTL brain regions. 
This would be consistent with the hypothesis that not all AD histopathology 
begins in the MTL, and these hippocampal-sparing conditions suggest that 
additional mechanisms must be considered in the genesis of spreading 
pathology in AD.   
The summary of my findings for each of these atypical syndromes, lvPPA 
and PCA, are as follows. LvPPA patients exhibited some degree of impairment of 
a measure of verbal episodic memory. I found this deficit observed in lvPPA was 
due in part to their limited lexical retrieval. This was associated with atrophy of 
left MTG, and not related to MTL/hippocampal atrophy, as in the typical AD 
cases (Win et al. 2017). Likewise, performance on a measure of visual episodic 
memory performance in PCA was impaired and this appeared to be due in part to 
difficulty perceiving in geometric design that had to be remembered. This deficit 
was not related to MTL/hippocampal atrophy, unlike the typical AD cases. 
Rather, their visual episodic memory difficulty appears to be mediated in part by 
disease in parietal regions including the precuneus. The effect of precuneus was 
significantly predicted by the visual episodic memory performance in PCA. 
Braak staging (Braak and Braak 1991) suggests that AD pathology in 
typical AD cases begins in MTL/hippocampus. However, this does not appear to 
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be true for all forms of AD histopathology. AD pathology in atypical cases of AD, 
such as lvPPA and PCA, may not begin in the hippocampus/MTL. Other studies, 
along with my research, corroborated this theory. Here, I report that atypical 
cases with AD pathology have minimal MTL/hippocampal disease, and their 
difficulty on measures of episodic memory appears to be due in part to other, 
non-MTL brain regions. MTL/hippocampus consists of multiple subregions and a 
specific subregion may be differentially affected that can interfere with memory 
performance but cannot be detected with a regular T1 brain imaging. My 
research employed a fine-grained T2 imaging sequence, that maximizes the 
visualization of the hippocampal and extrahippocampal subregions to 
qualitatively and quantitatively examined the differential involvement of these 
subregions. Even with this high resolution imaging, there is no significant 
changes in subregions of the MTL/hippocmapus in lvPPA or PCA. This result is 
consistent with the notion of hippocampal-sparing variant of AD (Murray et al. 
2011). Clinical evaluations of the atypical variants of AD may show relative 
sparing of memory but the neuropsychological evaluation of verbal episodic 
memory in lvPPA and visual episodic memory in PCA exhibited some degree of 
impairment. This research may provide important clues about how AD spreads, 
and highlights the eligibility of atypical variants of AD for clinical trials despite the 
absence of significant episodic memory difficulty.  
Poor performance on the delayed free recall task in lvPPA is a 
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confounding factor and can be confused with true verbal episodic memory 
difficulty mediated by MTL/hippocampal atrophy. As shown above, the inability to 
produce the words on the free recall task after a delayed period in lvPPA patients 
is due in part to their deficit in phonological retrieval of words. Some studies 
evaluating memory in lvPPA patients claimed that verbal memory was equally as 
impaired as patients with typical AD (Flanagan et al. 2014; Ramanan et al. 2016).  
In fact, these studies did not examine carefully the potential role of a lexical 
retrieval impairment that can influence on verbal episodic memory. My research 
demonstrated that there may be a common cognitive mechanism shared by 
lexical retrieval and verbal episodic memory, and suggested that the neural 
component underlying the common component is left MTG. My research also 
exposed the weakness of the delayed free recall task for lvPPA patients to 
assess memory. A better measure to show a relative sparing of memory, which is 
one of the criteria, is to use verbal recognition memory, which is less confounded 
by the lexical retrieval deficit. Future studies should carefully implement verbal 
memory measures that do not require lexical retrieval to better cater to a 
neurodegenerative population with impaired lexical retrieval when assessing 
verbal episodic memory. 
Similarly, poor performance on a measure of visual episodic memory was 
observed in patients with PCA. Examination of visual episodic memory in PCA 
was challenging due to their visuoperceptual and visuospatial problems. One 
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traditional way to assess visual episodic memory is using Rey Figure Recall test. 
Studies characterizing neuropsychological profile of PCA patients did not report 
the performance on measures of visual episodic memory recall. Here, we 
examined carefully the performance of Rey Recall in PCA patients and its neural 
correlate. By accounting for their visuoperceptual difficulty, my research 
demonstrated that precuneus, along with other parietal areas, mediates the 
visual episodic memory performance as well as visual perceptual difficulty. 
There are some limitations of my research. Detailed limitations associated 
with each of my studies have been addressed in respective section. Here, I will 
briefly discuss additional limitations. One of the shortcomings of my research is 
the use of the retrospective data on neuropsychological measures. This limited 
the nature of the specific neuropsychological measures that were available and 
resulted in some potential confounds that clouded interpretation of the results. 
Not all the patients who are diagnosed as lvPPA or PCA patients have 
neuropsychological measures available, further contributing to the small sample 
size. Larger cohorts of lvPPA or PCA patients are needed to assess these brain-
behavior relationships reported in my studies more reliably.  CSF was available 
in many of the patients that were examined, and while the results were consistent 
with likely AD pathology, it might have been better to examine autopsy brains in 
these cases to determine more directly the locus of pathology. Moreover, there 
was no CSF available in a few cases of the patient cohort. So I cannot rule out 
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that another pathologic condition may be underlying the typical lvPPA or PCA 
cases observed in the cohort of my research.  
Indeed, although lvPPA and PCA are atypical cases of AD, and majority of 
these cases are associated with AD pathology, the biology underlying the 
pathology of lvPPA and PCA patients may differ. Some cases of lvPPA patients 
have been reported to be associated with FTLD-U pathology, which is negative 
for tau immunoreactivity but positive for ubiquitin immunoreactivity (Mesulam et 
al. 2008). Schott and colleagues (2016) reported that the genetic risk factors 
associated with PCA are in or near APOE, CR1 (chromosome 1), ABCA7 (ATP-
binding cassette, sub-family A, member 7), BIN1 (bridging integrator 1).  In 
addition, exploratory genome-wide association studies in these PCA patients 
(Schott et al. 2016) identified three novel loci: rs76854344 near CNTNAP5 
(Contactin-associated protein-like 5); rs72907046 near FAM46A (Family with 
sequence similarity 46); and rs2525776 near SEMA3C (Class III Semaphorin 
3C). These studies suggest the different genetic profile between the atypical 
variant of AD cases; additional molecular factor may be driving the distribution of 
NFT in lvPPA and PCA.  
It would have been valuable to have longitudinal data to observe whether 
pathology in these atypical cases spread to the MTL as the disease progresses. 
Because my findings on lvPPA and PCA patients were single cross-sectional 
snapshot, the pattern of atrophy captured in lvPPA and PCA patients were more 
		
	
84	
focal and could be anywhere in the disease spectrum of typical AD. As the 
disease progresses, it is plausible for lvPPA and PCA patients to convert to 
typical AD. In addition, there was no known functional imaging data to provide 
further converging evidence on the performance of verbal episodic memory in 
lvPPA and visual episodic memory in PCA. Lastly, our cohorts of lvPPA and PCA 
was relatively young, as was our matched AD group. Caution thus must be 
exercised in generalizing our findings to late-onset patients with these 
syndromes. 
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Section IV.B. Future Directions 
The diagnostic criteria for lvPPA (Gorno-Tempini et al. 2011) and PCA 
(Crutch et al. 2017) require relatively spared episodic memory. As shown here, 
lvPPA patients perform poorly on the verbal delayed free recall task while their 
recognition memory is comparable to healthy seniors (Win et al. 2017). 
Recognition memory appear to be a better assessment of memory for lvPPA 
patients and there may be some advantages to incorporating verbal recognition 
memory as part of the criteria when diagnosing lvPPA patients rather than 
broadly requiring the sparing of episodic memory. Their lexical retrieval deficit 
has a significant effect on performing the delayed free recall task. Future studies 
should develop episodic memory measure that does not rely heavily on lexical 
retrieval when assessing neurodegenerative population. Similarly, my research 
showed that PCA patients do perform poorly on the Rey Figure Recall test while 
they perform comparable to the healthy seniors on the verbal recall measure. 
Hence, current diagnostic criteria for PCA patients should further elaborate on 
which domain (verbal or visual) of episodic memory should be spared since 
visual episodic memory is indeed affected in PCA cases due in part to disease in 
parietal brain regions that also contribute to visual-perceptual functioning. 
The longitudinal studies to track the disease progression in these atypical 
variant of AD are scarce. Rohrer and colleagues (2013) reported the longitudinal 
study of lvPPA patients revealed more involvement of posterior regions, including 
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atrophy in posterior cingulate/precuneus bilaterally, as well as involvement of 
anterior temporal and MTL regions. Moreover, lvPPA patients displayed a trend 
for a greater left/right hemisphere ratio over time compared to healthy controls; 
the rate of atrophy of the left hemisphere in lvPPA patients was greater than that 
of the right hemisphere. Consistent with the longitudinal anatomical changes in 
left temporo-parietal junction, lvPPA patients performed worse over time on 
sentence level processing associated with single word comprehension, 
repetition, and verbal recall (Rohrer et al. 2013). By criteria (Gorno-Tempini et al. 
2011), lvPPA patients display relatively intact recognition memory. Longitudinally, 
the cognitive and neuroanatomical profile in lvPPA patients may not confined to 
areas related to initial symptomatology. Future studies should investigate the 
performance of verbal recognition memory and visual episodic memory in lvPPA 
patients as the disease progresses and observe whether the involvement of MTL 
regions has an impact on verbal recognition memory and visual episodic 
memory.  
One serial imaging study observed alteration in the pattern of atrophy in 
PCA and AD over time (Lehmann et al. 2012). This study showed that compared 
to healthy controls, both the PCA and typical AD patients had significant atrophy 
changes in temporal and parietal regions more globally as the disease 
progresses. Here, I reported that visual episodic memory in PCA patients was 
affected and it was a true memory difficulty contributed by precuneus. Even after 
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taking into an account of visuoperceptual difficulty, measured by copied recall 
(percent of recall based on the individual performance on copy), the precuneus 
effect still remained. On the other hand, the MTL regions and precuneus 
mediated visual episodic memory difficulty in typical AD patients. After taking into 
an account of visuoperceptual difficulty in typical AD patients, measured by 
copied recall (percent of recall based on the individual performance on copy), the 
MTL effect still remained.  Future longitudinal studies should investigate whether 
PCA cases progress from an initially focal presentation to a more global pattern 
of atrophy, including MTL regions, and converge to the clinical presentations of 
AD over time. These studies also should examine whether MTL regions, if 
affected over time in PCA patients, contribute in part to visual episodic memory 
difficulty, in addition to the involvement of precuneus.   
My research, along with previous reports (Murray et al. 2011; Janocko et 
al. 2012), hope to illuminate that AD is a very complex and heterogeneous 
disease. This concept of heterogeneity of AD has been increasingly recognized 
over the past decade but it was originally discussed in 1969 (McDONALD 1969). 
McDonald (1969) reported two distinct subgroups among dementia patients he 
was seeing in his clinic; the first group of patients had prominent memory 
disorder and the second group of patients exhibited prominent difficulties with 
praxis, visual construction, and cortical sensation, and he called these patients 
‘parietal group’. However, most people at the time believed that different stages 
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of the disease progression conferred clinical variation (Ritchie and Touchon 
1992). Hence, McDonald’s findings of AD heterogeneity as well as AD subtype 
variability were not recognized (Ritchie and Touchon 1992) until PET imaging. 
Early PET studies demonstrated the distinct patterns of brain hypometabolism 
among AD subjects (Foster et al. 1983; Haxby et al. 1985); although these 
patients had memory impairments, participants with left hemispheric 
hypometabolism had greater language deficit while participants with right parietal 
hypometabolism had visuospatial impairment (Chase et al. 1984; Duara et al. 
1986). Fisher and colleagues (1997) also reported different subtypes of AD 
based on different neuropsychological profiles using the CERAD (Consortium to 
Establish a Registry for Alzheimer’s Disease) database: individuals with anomia 
displayed prominent left hypometabolism while impairment of constructional 
praxis displayed prominent right hemispheric hypometabolism (Fisher et al. 1996; 
1997a; 1997b). The participants in his study had the same age of onset, 
suggesting the different profile seen in these subtypes were the true variants and 
were not due to different stages in the disease progression. Longitudinal follow-
up studies further supported the distinct subtypes of AD by showing how these 
subtypes remained different over time (Grady et al. 1986; Fisher et al. 1997b). In 
the recent report on AD subtypes (Murray et al. 2011), hippocampal sparing 
variant AD cases account for 11% of the cases that was studied in Murray’s 
cohort.  
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Since Alois Alzheimer discovered AD in 1906, much progress in 
understanding the disease has been made in clinical, molecular, and 
neuroimaging fields (Hardy 2006). Despite these arduous efforts, clinical trials for 
AD patients have failed; the Food and Drug association (FDA) approved drugs 
for managing AD was based on research that were done three decades ago 
(Beach 2017). The most recent FDA approved therapeutic agent is directed at 
blocking glutamatergic excitotxicity (Memantine / Namenda) in 2003, while 
agents targeting the cholinergic supplementation, which was suggested back in 
1970s, is still at large for current therapy.  Clinical trials using the agents to 
reduce the amyloid aggregation (i.e. Tramiprosate, Tarenflurbil) have been 
targeting at the stages of mild to moderate AD dementia; these trials failed to 
support efficacy in AD dementia patients.  
Once the significant neuronal insult has occurred, anti-Aβ intervention 
appears unlikely to succeed; which was the case in triple-transgenic mouse 
models of AD (Oddo et al. 2004). Hypothetical models examining the 
pathological marker of Aβ show the neuronal insult has already taken place 
downstream of Aβ aggregation, which occur even prior to this prodromal stage 
(Jack et al. 2010; Rowe et al. 2010). Using the longitudinal Aβ information 
available in 89 healthy seniors with up to 10 years of follow-up, Insel and 
colleagues (2017) combined the level and rate of change of Aβ to estimate the 
time to Aβ-positivity for each participant and to significant Aβ pathology for 
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associations with brain structure, metabolism, and cognition using mixed-effects 
models (Insel et al. 2017a). They reported that accelerated rates of FDG-PET 
were observed to occur 20 years or more before the conventional threshold for 
Aβ-positivity while subtle signs of cognitive dysfunction were observed 10 years 
or more before Aβ-positivity (Insel et al. 2017b). Hence, even intervention made 
at a prodromal stage of AD in MCI patients during Phase II testing of therapeutic 
agents may be too late. 
According to the Alzheimer’s Association (2017), it is estimated that 5.5 
million Americans are living with AD in 2017. Of these, 5.3 million are over 65 
years of age and ~ 200,000 individuals have younger-onset Alzheimer's (under 
the age of 65).  It is reported that deaths from AD have increased by 89% while 
heart disease have decreased by 14% since 2000. Not only it is costly and 
burdensome on the AD patients themselves for atypical variants of AD, it is also 
stressful for the caregivers due to the care responsibilities since AD patients. As 
the disease progresses, patients cannot left alone due to worsening impairment 
in multiple cognitive domains. Without a doubt, the caregivers of AD patients are 
at greater risk of health problems, such as clinical depression, and 
cardiovascular disease (reviewed in Ross and Carroll 2017). These challenges 
are exacerbated in cases of atypical variants of AD cases with minimal memory 
difficulty due to the additional delay in making an accurate diagnosis.  It is, 
therefore, paramount to develop approaches for managing care for AD patients. 
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To add to this unfortunate epidemic problem, with more than half of 
hippocampal sparing AD patients being misdiagnosed. Dr. Melissa Murray 
suggested that over 600,000 Americans make up the hippocampal sparing AD 
variant (AAN talk, 2016). While there are myriads of strides for therapy for typical 
AD patients, even for those at the prodromal stage, the clinical trial for therapy for 
these atypical variants of AD are scarce. Patients with atypical variants of AD are 
not eligible for the traditional AD clinical trials even though the underlying 
pathology for majority of these cases is AD. It is my hope that this research 
further adds value to demonstrate that these atypical variants of AD (at least in 
lvPPA and PCA) exhibit the appearance of memory difficulty. Due to the 
heterogeneity within the AD spectrum, lvPPA and PCA patients will benefit more 
from the precision medicine. Hopefully, there will be more focused and 
specialized trials for these atypical variants of AD cases in the near future for 
therapeutic treatment.  
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ABBREVIATION INDEX 
 
ABCA7 = ATP-binding cassette, sub-family A, member 7 
AD = Alzheimer’s disease 
APOE4 = Apolipoprotein ε4  
BIN1 = bridging integrator 1 
BNT = Boston Naming Test 
CA = cornu ammonis 
CR1 = chromosome 1 
DG = dentate gyrus 
ERC = entorhinal cortex 
FDG = fluorodeoxyglucose  
GM = Gray matter  
JOLO = Judgment of Line Orientation test 
LvPPA = logopenic variant of primary progressive aphasia  
MMSE = Mini-Mental State Examination  
MTL = medial temporal lobe 
PCA = posterior cortical atrophy  
PET = Positron emission tomography 
ROI = region of interest  
TFCE = threshold-free cluster enhancement  
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